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ABSTRACT 
 
The past few decades of research have accumulated a body of evidence that membrane 
lipids are far more than merely the structural components of biological membranes. Instead, 
membrane lipids play important roles in cellular functions in multiple ways. Sphingolipids are a 
group of lipids that are involved in various cellular processes that are crucial for cell survival and 
proliferation. However, our understanding of sphingolipid function is limited due to the 
complexity of their behaviors and the lack of proper tools to address and decipher this 
complexity.  
Chapters 2 and 3 present metabolic labeling with fluorophores and stable isotope tags, 
respectively, as tools to investigate sphingolipid behaviors. Metabolic labeling enables one to 
detect and directly observe sphingolipids, and not the activities or levels of the enzymes that 
metabolize them. Metabolic labeling of cells with fluorescent sphingosines enabled visualization 
of the sphingosine metabolites in live cells and also showed potential for studies of metabolism 
and in vitro assays. Use of stable isotope tagged sphingolipid precursors, in conjunction with 
LC-MS/MS analysis, provided a more comprehensive and complete dataset than traditional 
radiolabeling, including information about unlabeled as well as labeled species. These tools 
offer great opportunities to explore sphingolipid behaviors.  
In Chapter 4, based on the observations that sphingolipids have significant roles in 
membrane organization and that virus infection requires intense membrane reorganization, the 
involvement of acid sphingomyelinase or sphingomyelin phosphodiesterase 1 (SMPD1), a 
sphingolipid metabolizing enzyme, in influenza virus infection and particularly its entry was 
evaluated using RNAi and a pharmacological inhibitor. Western blotting performed prior to 
infection showed that a significantly higher level of SMPD1 was present in the medium than in 
the cells. Lowering SMPD1 levels by RNAi or a functional pharmacologic inhibitor, desipramine, 
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did not cause a statistically meaningful change in influenza virus entry. However, influenza virus 
infection itself was correlated with upregulated SMPD1 levels at the early phase of infection, 
opening the possibility that sphingolipids may still play an important role in influenza virus 
infection. Further investigation of the role of SMPD1 in influenza virus infection is necessary. 
Lastly, in Chapter 5, the cellular uptake of protein-coated nanoparticles was investigated 
in an effort to understand how plasma proteins interact with the nanoparticle surface, and to 
enhance the efficiency of targeted nanoparticle delivery with an in vitro system that mimics the 
in vivo environment. Formation of the protein corona, the protein layer that adsorbs on the 
surface of the nanoparticle when it is exposed to a biological fluid, is reported to prevent the 
desired interactions between the nanoparticles and the target cells. Exploiting the well-
established mechanism of opsonin-mediated endocytosis in immune cells, we tested whether 
the protein corona itself can be used as a targeting moiety. Pre-coating the nanoparticles with γ-
globulins provided a simple route to enrich the protein corona with opsonins. However, the 
increased opsonin levels in the protein corona did not enhance cellular uptake, but instead 
significantly decreased it. Immunodot blot assay and confocal fluorescence microscopy showed 
that these nanoparticles were internalized through opsonin-receptor interactions, but the 
opsonins on the nanoparticle were not accessible. This indicates that other components in the 
protein corona shielded the opsonins, preventing them from interacting with their target 
receptor. This study demonstrates that the spatial organization of the targeting moieties is 
critical, and it must be optimized for more efficient targeted nanoparticle delivery.   
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CHAPTER 1 
INTRODUCTION 
 
1.1 MEMBRANE LIPIDS 
Every cell has a plasma membrane that separates itself from the surrounding 
environment. In addition, the organelles within eukaryotic cells are also surrounded by 
membranes. Cellular membranes consist of a self-assembled lipid bilayer. The fluid mosaic 
model suggests that the lipids in the membrane have fluid-like properties that allow membrane 
proteins to freely diffuse in the lateral direction.1 Consequently, membrane lipids were once 
thought to merely function as structural components of cellular membranes. However, the past 
few decades of research have revealed that membrane lipids are not just structural components 
of cellular membranes, but they also play important, active roles in mediating diverse cellular 
functions.   
Several mechanisms of how membrane lipids are involved in biological functions have 
been hypothesized and studied. First, certain membrane lipids, specifically sphingolipids and 
sterols, are thought to form functionally and compositionally distinct lipid domains in plasma 
membranes and more recently, nuclear envelops.2-4 Second, some lipids are enzymatically 
converted to metabolites that act as second messenger signaling molecules by activating 
downstream signaling events.5,6 For instance, the conversion of phosphatidylcholine (PC) to 
diacylglycerol (DAG) at the plasma membrane activates protein kinase C (PKC), triggering 
downstream signaling.7 Lastly, some lipids bind directly to proteins and regulate the proteins’ 
activities. Many proteins have lipid binding domains, such as C2 domains or SH domains that 
can precisely regulate their location and activities.8 The direct and selective binding of specific 
lipid species to certain proteins that lack typical lipid binding domains have been also observed. 
COPI machinery protein p24 interacts specifically with C18 sphingomyelin (sphingomyelin that 
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is acylated with stearic acid, a saturated 18-carbon fatty acid) and regulates COPI dependent 
transport in the cells.9 C99, a protein generated from full-length amyloid precursor protein (APP) 
by ß-secretase, binds to cholesterol through GXXXG motifs; this binding affects the protein’s 
conformation and enhances its cleavage by γ-secretase, which produces Aß polypeptides.10  
Membrane lipids can be generally categorized into three classes, sterols, glycero-
phospholipids, and sphingolipids. Structurally, sterols are distinct from other membrane lipids 
due to their polycyclic ring structure. Cholesterol is a sterol lipid that is abundant in mammalian 
membranes, comprising approximately 30-40 mol% of all plasma membrane lipids.11 Sterols are 
the major non-polar membrane lipid and are known to affect membrane fluidity and 
organization.12,13 
Glycerophospholipids are a major structural membrane lipid class that comprises about 
50 mol% of the plasma membranes.11 Glycerophospholipids have two hydrophobic fatty acids 
and a hydrophilic head group that are attached to the glycerol backbone. This class includes 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phospha-
tidylinositol (PI), and phosphatidic acid (PA). In healthy cells, glycerophospholipids are 
heterogeneously distributed across the plasma membrane. Typically, PC is in the outer leaflet 
(exoplasmic leaflet) while PE and PS are primarily located in inner leaflet (cytosolic leaflet). This 
heterogeneity is maintained by lipid flippases and scramblases in the membranes.11  
Sphingolipids are distinguished from glycerophospholipids by their sphingoid backbone. 
The amine moiety in this sphingoid backbone allows hydrogen bonding among sphingolipids or 
other membrane lipids, such as cholesterol.11 Most membrane sphingolipids are N-acylated. 
Sphingomyelins, the most abundant sphingolipid in mammalian cells, have a phosphocholine 
head group, analogous to PC in the glycerophospholipid family. About 10-15 mol% of 
mammalian plasma membrane lipids are sphingolipids. Sphingolipids are discussed in more 
detail in the next section.  
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1.2 SIGNIFICANCE OF SPHINGOLIPIDS  
Sphingolipids have been of great interest due to their significance in many pathological 
conditions.14 Mutations in certain sphingolipid metabolic enzymes directly cause lysosomal lipid 
storage diseases that often present progressive neurodegeneration.15 Aberrant levels of 
sphingolipids or sphingolipid metabolic enzymes have been also reported in many other 
pathological conditions. Ceramide synthase and ceramide levels were found to be statistically 
and significantly higher in malignant tumor tissue that the corresponding healthy tissue.16 
Inflammation is indicated to alter sphingolipid metabolism,5 and impaired sphingolipid 
metabolism is associated with Alzheimer’s disease.17 Sphingolipids have proven to be a 
successful target for the treatment of multiple sclerosis. Specifically, fingolimod (FTY720), a 
FDA approved immunomodulatory drug that is taken orally to treat multiple sclerosis, is a 
structural analogue of sphingosine.18 The involvement of sphingolipids in infections will be 
discussed in Chapter 4.  
Sphingolipids and their metabolites are involved in numerous cellular signaling events in 
which they trigger downstream effectors that are important for biological functions. A number of 
comprehensive reviews on how sphingolipids regulates signaling events in the cells have been 
published.5,19-27 Ceramides, sphingosine, and sphingosine-1-phosphate (S1P) are among the 
well-known bioactive sphingolipid molecules. Ceramides mediate various stress responses, 
such as apoptosis and cell growth arrest.19 Ceramides can interact with a number of signaling 
molecules, including kinase suppressor of Ras (KSR), atypical protein kinase-C (aPKC), c-Raf-
1, cathepsin D, protein phosphatase 2A (PP2A) and ceramide-activated protein phosphatase.22 
The physiological mechanisms through which ceramides regulate those signaling events are still 
not clear. In the classical view, ceramides have been thought to be a second messenger that 
affects the activity or localization of signaling proteins. However, recent data challenge this view 
and support the alternative model where changes in local ceramide levels alter membrane 
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organization and, in turn, change the localization of certain proteins.22 In addition to ceramide, 
sphingosine can also affect cellular signaling events. Sphingosine inhibits the anti-apoptotic 
function of 14-3-3 proteins by binding to them, which regulates their phosphorylation.28 
Sphingosine can also inhibit PP2A by binding to PP2A inhibitors ANP32a and ANP32b.22 
Sphingosine can be phosphorylated by sphingosine kinases. The phosphorylated product, S1P, 
is known to be pro-survival and mitogenic. S1P is a ligand for five S1P receptors (S1PRs). 
These S1PRs are G-protein coupled receptors (GPCRs, also known as 7 transmembrane (7TM) 
receptors). Each receptor triggers different downstream G protein(s) and induces different 
biological consequences.25-27 Through these receptors, S1P regulates migration,29 cytoskeletal 
organization,30 angiogenesis and vasculogenesis.31,32 Due to the opposite outcomes of 
ceramides and S1P signaling, the sphingolipid rheostat model has been hypothesized. The key 
concept of the sphingolipid rheostat model is the balance between pro-apoptotic ceramides and 
pro-survival S1P. Imbalance between two signaling molecules is associated with diseases, such 
as cancer and diabetes.33-36 
Lastly, sphingolipids have been intensely studied in a biophysics perspective. 
Sphingolipids form lipid domains that are physically and chemically distinct from non-domain 
regions. Super-resolution fluorescence microscopy and high-resolution imaging mass 
spectrometry have independently demonstrated the presence of sphingolipids-enriched 
domains in the plasma membrane.3,37 Sphingolipids have the capability to create curvature in 
the membrane. The conversion of sphingomyelin to ceramide significantly reduces the size of 
the head group. Such decrease in lipid head group size is known to induce curvature in model 
membranes.38,39 This ceramide-induced curvature has been suggested to mediate membrane 
repair and exosome sorting. When the cells are wounded, lysosomal acid sphingomyelinase 
leaks out of the cells and converts sphingomyelins to ceramides in the plasma membrane, 
which can create an invagination that initiates endocytosis of the damaged region of the 
membrane.40 Neutral sphingomyelinases can produce similar effects inside the cells. This 
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neutral sphingomyelinase-dependent ceramide production has been shown to induce exosomes 
to bud into multivesicular endosomes.38 
In summary, sphingolipids have significant roles in numerous cellular processes, and 
multiple mechanisms may be responsible for their actions. Therefore, it is critical to understand 
sphingolipid metabolism and behavior inside cells. 
 
1.3 SPHINGOLIPID METABOLISM AND TRAFFICKING 
Ceramides are at the center of sphingolipid metabolism. Ceramides are synthesized at 
the endoplasmic reticulum (ER) by the N-acylation of sphingoid backbones. The sphingoid 
backbones can be produced by the de novo pathway from the condensation of serine and 
palmitoyl CoA by serine palmitoyltransferase and then reduction by 3-ketodihydrosphingosine 
reductase, or by the degradation of complex sphingolipids at the lysosomes. Ceramides can be 
further processed to more complex sphingolipids that have larger head groups, such as 
sphingomyelins, glycosphingolipids, or gangliosides, and this mostly occurs at the Golgi 
apparatus. Ceramides can be also deacylated to produce sphingosine and a fatty acid. The 
resulting sphingosine can be reused to produce ceramide or phosphorylated to S1P.  As 
discussed above, S1P is a ligand for S1P receptors, which are G protein coupled receptors that 
are involved in cell proliferation, migration, and many other biological functions. S1P can also be 
irreversibly catabolized to hexadecenal and ethanolamine phosphate by sphingosine-1-
phosphate lyase. Sphingolipid metabolism is described in detail in Figure 1.1. 
The intracellular distribution of sphingolipids is controlled by sphingolipid metabolism and 
transport. Organelle-specific enzymes regulate local sphingolipid levels. Ceramide synthase in 
the ER is responsible for ceramide synthesis. The conversion of ceramides to sphingomyelins 
or glycosphingolipids is carried out by transferases, namely sphingomyelin synthase and 
ceramide glucosyltransferase, in the Golgi apparatus. Sphingolipids are also metabolized at the 
plasma membrane. Sphingomyelin synthase 2 (SMS2) and neutral sphingomyelinases 2 
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(nSMase2) are found at the plasma membrane. Mitochondria also contain a neutral 
sphingomyelinase that is known to be specific to mitochondria.41 At the lysosomes, 
sphingolipids are degraded by acidic catabolic enzymes, such as acidic sphingomyelinase 
(aSMase) and acid ceramidase. Therefore, organelle-specific sphingolipid metabolic enzymes 
are found in almost every organelle in the cell.  
Sphingolipid transport has a huge impact on sphingolipid distribution throughout the 
cells. For instance, the level of sphingolipids is very low at the ER where sphingolipid synthesis 
takes place, which suggests that sphingolipids are rapidly transported out of the ER. The 
majority of sphingolipids are found in the plasma membrane, and this is thought to result from 
vesicular trafficking from the ER to the Golgi and then to the plasma membrane. Nonvesicular 
sphingolipid transport has also been reported. CERT (ceramide transfer protein) and FAPP2 
(four-phosphate-adaptor protein 2) transfer ceramide from the ER to the trans-Golgi and 
glycosphingolipids from the trans-Golgi network to the plasma membrane, respectively.42-44 This 
nonvesicular trafficking of ceramide from the ER to the Golgi is necessary for the synthesis of 
sphingomyelin, but not glucosylceramide.44  
In summary, the subcellular distributions of sphingolipids are regulated and maintained 
by their metabolism and trafficking.  
 
1.4 NOVEL TOOLS TO STUDY BEHAVIORS OF SPHINGOLIPIDS 
Since sphingolipid metabolic enzymes were cloned,45-47 many of them have been 
manipulated by overexpression,48 knock-out by gene targeting,49,50 or downregulation using 
RNAi51 or pharmacological drugs52,53 to probe the roles of sphingolipid metabolism in many 
different signaling pathways. Much less effort has been made to directly measure the local 
intracellular abundances of specific sphingolipid species or track their transport in the cell. Yet, 
much research suggests the direct involvement of sphingolipids such as ceramides and S1P,19 
and not the enzymes that produce them, in signaling events, whereas the sphingolipid metabolic 
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enzymes play secondary roles, namely regulating the levels of bioactive sphingolipids. 
Therefore, to truly understand how sphingolipids affect cell signaling and function, more efforts 
should focus on to directly measuring and observing sphingolipids. For this reason, I aimed to 
utilize metabolic labeling with fluorescently labeled sphingolipid precursors (Chapter 2) and 
stable isotope-labeled sphingolipid precursors (Chapter 3) to investigate sphingolipid behaviors. 
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1.6 FIGURES 
 
  
 
 
Figure 1.1. Metabolic pathways of sphingolipids. 
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CHAPTER 2 
DEVELOPMENT AND USE OF FLUORESCENT SPHINGOSINES FOR INVESTIGATING 
SPHINGOLIPID BEHAVIORS* 
 
2.1 INTRODUCTION 
Sphingolipids and their metabolites serve both as structural components in eukaryotic 
cell membranes and as bioactive signaling molecules that modulate gene expression, 
apoptosis, and other critical cellular processes during normal cell function and disease.1-4 Insight 
into sphingolipid biosynthesis, transport, and subcellular distribution has been acquired by 
observing fluorescent sphingolipid analogs within living cells.5 Sphingolipid derivatives that 
contain a fluorophore-labeled N-acyl fatty acid are often employed to investigate dynamic 
processes that involve acylated sphingolipids.5 Fatty acids that contain a polyene fluorophore 
are especially attractive for this purpose because the structure and behavior of polyene-
containing lipids are very similar to the native lipid.6 However, to study the bioactive, unacylated 
sphingolipids, sphingosine and sphingosine-1-phosphate, the fluorophore must instead be 
incorporated into the sphingosine backbone. Studies have confirmed that such fluorescent 
																																																						*	 This chapter features portions of the work that was originally appeared in and has been 
reprinted with permission from: Journal of Lipid Research. Kim, R., Lou, K. & Kraft, M. L. “A 
new, long-wavelength borondipyrromethene sphingosine for studying sphingolipid dynamics in 
live cells”, Journal of Lipid Research 54, 265-275 (2013).  
The publication in the Journal of Lipid Research was coauthored by Raehyun Kim, Kaiyan Lou, 
and Mary L. Kraft. R.K. characterized the fluorescence properties of the fluorescent 
sphingolipids, developed the experiment protocol for cell labeling, prepared and analyzed cell 
samples and cellular lipid samples. K.L. designed and synthesized the fluorescent sphingosines 
and assisted lipid analysis. M.L.K. planned and designed the experiments. 
I thank Sean Sihoon Park for his assistance with the preparation of organelle marker plasmids, 
Lauren Macur Brousil for her assistance with the TLC separation.  
M.L.K. held a 2007 Career Award at the Scientific Interface from the Burroughs Wellcome Fund. 
This material is based upon work supported by the National Science Foundation under CHE–
1058809. 
Portions of this work were carried out in the Core Facility in the Carl R. Woese Institute for 
Genomic Biology and Protein Sciences Facility in the Roy J. Carver Biotechnology Center at the 
University of Illinois at Urbana-Champaign. 
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sphingosine analogs can be metabolized to more complex fluorescently labeled sphingolipids in 
living cells.7-10 Despite their potential utility, only a limited number of fluorophores, such as 
pyrene, borondipyrromethene (BODIPY), and nitrobenzo-2-oxa-1,3-diazole (NBD), have been 
incorporated into the sphingosine backbone.7-9  
To increase the utility of fluorescent sphingosine analogs for investigating sphingolipid 
dynamics in living cells, derivatives with a wider range of fluorescence properties must be 
developed. Lacking in particular is a bioactive fluorescent sphingosine that has neither an 
excitation maximum that is in the UV range, nor emission that interferes with detecting green 
fluorescent protein (GFP), the most common genetically encoded fluorescent protein label.11 A 
probe with these properties is expected to have the advantages of lower phototoxicity than 
existing fluorescent sphingosine analogs, and the capability to visualize it in parallel with GFP, 
which would facilitate assessing sphingolipid colocalization with proteins of interest. For this 
reason, here we report the synthesis and validation of BODIPY 540 sphingosine, which has 
maximum excitation at 540 nm, and emission that does not overlap with GFP. In this study, we 
use fluorescent organelle-specific markers to characterize the distribution of BODIPY 540 
sphingosine and its fluorescent metabolites within living cells. We confirm that mammalian cells 
metabolized BODIPY 540 sphingosine to BODIPY 540 sphingolipids, and also catabolized 
these fluorescent sphingolipid metabolites. Based on these results, we anticipate that this new 
fluorescent sphingosine analog will be a valuable tool for investigating the metabolism, 
trafficking, and signaling of acylated and unacylated sphingolipid species in living cells.  
 
2.2 MATERIALS AND METHODS 
2.2.1 Synthesis of BODIPY 540 sphingosine, BODIPY 540 ceramide and BODIPY 540 
sphingomyelin standards  
BODIPY 540 sphingosine, BODIPY 540 ceramide and BOIDPY 540 sphingomyelin were 
synthesized as described.12 
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2.2.2 Cell culture  
NIH3T3 murine fibroblast cells (ATCC© CRL-1658) were grown in Dulbecco's Modified 
Eagle Medium (DMEM) with 10% calf serum and 1% penicillin/streptomycin in a 5% CO2 
incubator at 37°C. For colocalization studies, organelle-specific fluorescent fusion proteins were 
expressed in HEK293 cells due to their ease of transfection. HEK293 cells were grown in 
DMEM with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in a 5% CO2 
incubator at 37°C. For microscopy experiments, cells were cultured in 35 mm glass bottom 
dishes (MatTek, Ashland, MA) or 35 mm plastic dishes for high-end microscopy (ibidi GmbH, 
München, Germany). For all other experiments, cells were grown in 150 mm cell culture dishes. 
2.2.3 Pulse-chase labeling  
Cells were incubated with BODIPY 540 sphingosine in OptiMEM supplemented with 
either 2% calf serum (NIH3T3 murine fibroblast cells) or 2% FBS (HEK293 cells). BODIPY 540 
sphingosine was dissolved in ethanol and added to the labeling medium such that the final 
concentration of BODIPY 540 sphingosine was 1 or 1.25 µM. For pulse labeling, cells were 
incubated in labeling medium that contained either 1 or 1.25 µM of BODIPY 540 sphingosine for 
30 min. After labeling, the medium was removed, and the cells were washed with phosphate 
buffered saline (PBS) and then cultured in unlabeled growth medium for the specified chase 
time. For studies of BODIPY 540 sphingosine metabolism, cells were incubated in growth 
medium that contained 1 µM of BODIPY 540 sphingosine for the specified time.   
2.2.4 Lipid extraction 
Cells were harvested when they reached 90-100% confluence. Cells were washed with 
cold PBS, removed from the dish with a scraper, and pelleted by centrifugation. Lipids were 
extracted using the Bligh and Dyer method.13 The glycolipids were selectively hydrolyzed by 
alkaline treatment with sodium hydroxide; this treatment did not hydrolyze the sphingolipids. 
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2.2.5 TLC 
Lipids extracts were dissolved in chloroform-methanol (20 μL, 2:1 v/v), spotted on TLC 
plates (Silica 60 F254 plates, EMD Chemicals), and developed in a TLC chamber using butanol-
acetic acid-water (4.5:1:1 v/v/v) as the solvent. Digital imaging of the TLC plates was performed 
on a Typhoon 9400 imager (GE Healthcare) using 532 nm laser excitation and 580 nm emission 
filter to detect the fluorescent spots. Unlabeled lipids were visualized by iodine staining. The 
BODIPY 540-labeled sphingomyelin, ceramide, and sphingosine were identified by their co-
migration with BODIPY 540-labeled sphingolipid standards. Because this solvent system 
primarily separated the lipid species according to their head groups, which was confirmed by the 
co-migration of the BODIPY 540 labeled sphingomyelin and ceramide with unlabeled 
sphingomyelin and ceramide, respectively, in this solvent system, the remaining fluorescent lipid 
species were identified according to their co-migration with an unlabeled lipid standard. 
2.2.6 Glycerophospholipid quantification 
For each labeling interval (2 h and 1 d), the total lipid extract obtained from a single 
labeling experiment was dissolved in chloroform-methanol (2:1 v/v) and divided into two equal 
portions. One portion of the total lipid extract was subjected to alkaline hydrolysis to remove the 
glycerolipids; the resulting fraction is referred to as the sphingolipid extract because it contained 
primarily sphingolipid species. For each labeling time, the total lipid extract and corresponding 
sphingolipid extract were applied to a TLC plate and separated using butanol-acetic acid-water 
(4.5:1:1 v/v/v) as the solvent system. For each labeling interval, the amount of BODIPY 540-
labeled glycerophospholipids on the TLC plate was assessed by visualizing the spots with a 
Typhoon 9400 imager (GE Healthcare) using 532 nm laser excitation and 580 nm emission filter 
and quantifying their fluorescence intensities. To quantify the fraction of the fluorescence that 
corresponded to glycerolipids, the sum of the fluorescence intensities measured for each spot 
that corresponded to fluorescent phosphatidylcholine, phosphatidylethanolamine, phosphatidyl-
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serine, and phosphatidylinositol was measured using ImageQuant software (GE Healthcare) 
and divided by the total fluorescence intensities of all of the fluorescent lipid species.   
2.2.7 Labeling organelles for colocalization study 
For labeling the endoplasmic reticulum (ER), Golgi apparatus, and mitochondria, 
organelle-specific GFP protein constructs were employed. For ER labeling, HEK293 cells were 
transfected with pAc-GFPC1-Sec61β (Addgene plasmid 15108)14 using TransPass D2 
transfection reagent (New England BioLabs, Ipswich, MA). For Golgi apparatus and 
mitochondria labeling, CellLight® Golgi-GFP and CellLight® Mitochondria-GFP (Molecular 
Probes), respectively, were used according to the manufacturer’s protocol. One to two days 
after transduction, the HEK293 cells were incubated with 1 μM of BODIPY 540 sphingosine for 
30 min, followed by a chase in unlabeled medium for approximately 1 day. To label the 
lysosomes, NIH3T3 mouse fibroblast cells were incubated with OptiMEM containing 2 mg/mL of 
FITC-dextran (MW 10,000, Sigma-Aldrich) for 30 min. The cells were then cultured for 5 h in 
unlabeled medium, followed by 30 min in medium that contained 1 μM of BODIPY 540 
sphingosine, and finally in unlabeled medium for a 30 min or 16 h chase. To label the nucleus, 2 
μL of Hoechest 33342 (Invitrogen) stock solution (10 mg/mL) was added to the growth medium 
in which the NIH3T3 mouse fibroblast cells were cultured. After 30 min, the medium was 
replaced with unlabeled medium. After 30 min, the cells were incubated in medium with 1 μM of 
BODIPY540 sphingosine for 30 min, and then were transferred to unlabeled medium for a 2-day 
chase. 
2.2.8 Confocal laser scanning microscopy 
Labeled cells were transferred to phenol red-free OptiMEM supplemented with 2% calf 
serum (NIH3T3 mouse fibroblast cells) or 2% FBS (HEK293 cells). The labeled cells were 
observed on a Carl Zeiss LSM 700 confocal microscope with 63 X 1.4 NA oil immersion 
objective lens at room temperature using a 555 nm laser to excite BODIPY 540, a 488 nm laser 
to excite GFP and FITC, and a 405 nm laser to excite Hoechst 33342. 
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2.3 RESULTS 
2.3.1 Fluorescence property of BODIPY 540 sphingosine 
Characterization of the absorption and fluorescence of BODIPY 540 sphingosine in 
ethanol (1 μM) demonstrated its absorption and fluorescence emission maxima were 540 nm 
and 568 nm, respectively (Figure 2.1). Thus, the excitation and emission properties of the 
analog are similar to BODIPY TMR despite replacing the phenoxy methyl in BODIPY TMR with 
a sphingosine moiety. The long wavelength emission that is indicative of dimer formation 
appeared to be negligible in labeled cells. 
2.3.2 Cells uptake and metabolize BODIPY 540 sphingosine 
We first confirmed that BODIPY 540 sphingosine was internalized by cells and 
metabolized to more complex fluorescent sphingolipids. Mouse fibroblast cells (NIH3T3) were 
pulse labeled by incubation with 1.25 µM of BODIPY 540 sphingosine for 30 min at 37°C and 
transferred to unlabeled medium at 37°C for various chase times before imaging at room 
temperature. No adverse effect on cell viability was observed during or after labeling. Figure 2.2 
shows that the pulse-labeled cells exhibited strong fluorescence, confirming they internalized 
the BODIPY 540 sphingosine. After a 30 min chase in unlabeled medium, fluorescent tubule-like 
structures and vesicles of various sizes were observed inside the NIH3T3 mouse fibroblast cells 
(Figure 2.2A). The edges of these cells did not exhibit strong fluorescence, which indicates that 
the plasma membrane contained low levels of fluorescent lipid species (Figure 2.2A). 
Fluorescent vesicles were also observed in NIH3T3 mouse fibroblast cells when the duration of 
the chase in unlabeled medium increased to 20 h (Figure 2.2B). Although the plasma 
membrane still appeared to be dim relative to the highly fluorescent intracellular vesicles, which 
were especially abundant in NIH3T3 mouse fibroblast cells, the clearer fluorescent outline of the 
cell’s perimeter indicates that BODIPY 540 lipid species had incorporated into the plasma 
membrane (Figure 2.2B). Overall, these observations suggest that the BODIPY 540 
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sphingosine was metabolized to fluorescent sphingolipids, which were transported to the 
plasma membrane. 
To verify that the fluorescent sphingosine was metabolized fluorescent sphingolipids, 
NIH3T3 mouse fibroblast cells were cultured in the presence of 1 µM of BODIPY 540 
sphingosine for various time intervals, and their lipids were extracted. The glycerolipids in each 
total lipid extract were removed by base hydrolysis,15 and the resulting fraction, referred to as 
the sphingolipid extract because it primarily contained sphingolipids, was separated by TLC. 
The BODIPY 540-labeled sphingolipids on the TLC plate could be detected with high sensitivity 
according to their fluorescence. Four fluorescent sphingolipid species, which included BODIPY 
540 sphingosine, were detected after a labeling time as short as 2 h (Figure 2.2C). Co-migration 
with BODIPY 540-labeled sphingolipid standards confirmed that the NIH3T3 mouse fibroblast 
cells metabolized the fluorescent sphingosine to BODIPY 540-labeled ceramide and 
sphingomyelin. Because the BODIPY 540-labeled ceramide and sphingomyelin co-migrated 
with the analogous unlabeled sphingolipid in this solvent system, we identified the remaining 
fluorescent sphingolipid as BODIPY 540 glucosylceramide due to its co-migration with the 
unlabeled standard. In addition to these four sphingolipid species, a fifth species, identified as 
lactosylceramide based on its relative location on the TLC plate,16 was observed for a labeling 
period of 1 day. More complex BODIPY 540-labeled glycosphingolipids, such as BODIPY 540 
gangliosides, were not visible on the TLC plate. Because unlabeled gangliosides also were not 
detected on iodine-stained TLC plates, the inability to detect BODIPY 540 gangliosides likely 
reflects a low level of gangliosides in the NIH3T3 mouse fibroblast cell extracts and not a lack of 
BODIPY 540 sphingosine incorporation into complex glycosphingolipid species. 
Native sphingolipid catabolism yields phosphoethanolamine and the fatty aldehyde 
trans-2-hexadecenal, which is oxidized to a fatty acid that can be incorporated into 
glycerolipids.16-19 Therefore, if the BODIPY 540 sphingolipids were degraded via this pathway, 
the resulting BODIPY 540 labeled hexadecenal could be oxidized and used to biosynthesize 
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fluorescent glycerolipids. To assess this possibility, sphingolipid extracts and total cellular lipid 
extracts were isolated from NIH3T3 mouse fibroblast cells that were cultured in the presence of 
1 µM of BODIPY 540 sphingosine for 2 h, and the lipid components were separated with TLC. In 
addition to the BODIPY 540 labeled sphingolipid species observed by TLC separation of the 
sphingolipid extract, the total cellular lipid extract exhibited three additional fluorescent spots 
that corresponded to fluorescent glycerophospholipids (Figure 2.2C). Comparison of these 
migration patterns to those of unlabeled phospholipid standards indicated that two of these 
components were BODIPY 540 labeled phosphatidylcholine and phosphatidylethanolamine; the 
third spot was consistent with either BODIPY 540 labeled phosphatidylserine or 
phosphatidylinositol. Based on the relative intensities of the TLC spots corresponding to 
unlabeled lipid species, which were visualized by staining the same TLC plate with iodine, the 
BODIPY 540 fluorophore was incorporated into the major sphingolipid species but was less 
abundant in the major glycerolipid species after a 2 h labeling period. However, after labeling 
with 1 µM of BODIPY 540 sphingosine for 1 day, the BODIPY 540 labeled lipids reflected the 
major lipid species present in the cell extracts. These results suggest that fluorescent 
sphingolipid degradation followed the native sphingolipid catabolism pathway. 
We estimated the fraction of BODIPY 540 that had been incorporated into glycerolipids 
after labeling NIH3T3 mouse fibroblast cells with 1 μM of BODIPY 540 sphingosine for 2 h and 1 
day by measuring the fraction of the total fluorescence on the TLC plate that was produced by 
spots corresponding to glycerolipid species. After a 2 h labeling period, BODIPY 540 
glycerolipids produced approximately 25% of the fluorescence measured in the total lipid 
extract; after labeling for 1 day, approximately 43% of the fluorescence measured in the total 
lipid extract was produced by BODIPY 540 glycerolipids. Thus, the BODIPY 540 glycerolipids 
that resulted from BODIPY 540 sphingolipid catabolism were detectable after a pulse as short 
as 2 h, and their abundance increased with time. Previous studies have demonstrated that 
exogenous [3H]-sphingosine is also rapidly degraded by cells and that the amount of the 
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radioactive degradation products increases with time.20 This suggests that the time-dependent 
sphingolipid catabolism we observed is a characteristic of sphingosine pulse labeling and was 
not induced by the presence of the fluorophore. 
2.3.3 Subcellular distribution of BODIPY 540 sphingolipids 
The studies described above demonstrate that NIH3T3 mouse fibroblast cells 
metabolized the BODIPY 540 sphingosine to fluorescent sphingolipids and degraded these 
fluorescent sphingolipids in a manner that was consistent with native sphingolipid catabolism. 
We performed colocalization studies to confirm that BODIPY 540 sphingosine and its 
fluorescent metabolites were trafficked through the organelles where sphingolipid biosynthesis 
primarily occurs. For these experiments, HEK293 cells were used because their high 
transfectability facilitated the expression of the organelle-specific fluorescent proteins required 
to assess colocalization. HEK293 cells that expressed the ER or Golgi apparatus markers, 
GFP-Sec61β14 or CellLight® Golgi-GFP, respectively, were pulse labeled with 1 μM of BODIPY 
540 sphingosine for 30 min, followed by a 30 min or 1 day chase. Confocal microscopy imaging 
confirmed the fluorescent sphingolipid analogs were located in the ER (Figure 2.3A) and Golgi 
apparatus (Figure 2.3B) after the 30 min chase. Low colocalization occurred between the 
fluorescent sphingolipid analog and the ER or Golgi apparatus markers for the 1-day chase 
(Figure 2.3C and 2.3D, respectively). The transient colocalization of the BODIPY 540 with the 
ER and Golgi apparatus is consistent with the conversion of BODIPY 540 sphingosine to more 
complex fluorescent sphingolipids in these organelles and the subsequent transport of the newly 
synthesized fluorescent sphingolipids to the plasma membrane.21 
Lysosomes are the subcellular compartment where complex sphingolipids are 
catabolized to sphingosine,22,23 which can be reused for the biosynthesis of new sphingolipids, 
or degraded to nonsphingolipid species.17,18,24 We investigated whether BODIPY 540 
sphingosine or its fluorescent metabolites accumulated in lysosomes by assessing 
colocalization between the lysosome marker, FITC-dextran,25 and BODIPY 540. NIH3T3 mouse 
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fibroblast cells were labeled with FITC-dextran, pulse labeled for 30 min with BODIPY 540 
sphingosine, and subjected to a 30 min or 16 h chase. Confocal microscopy imaging of these 
cells demonstrated that low levels of colocalization occurred after a 16 h chase time (Figure 
2.4). The lack of BODIPY 540 accumulation in the lysosomes confirms that the fluorescent 
sphingolipids that reached the lysosomes were promptly degraded, and the resulting fluorescent 
products were exported from the lysosomes. 
We also investigated whether BODIPY 540 sphingosine or its fluorescent metabolites 
could be detected in the mitochondria or nucleus. We focused on these organelles because 
sphingolipids and their metabolites have been previously detected within them, and the 
sphingolipid metabolism that occurs within these organelles plays a major role in modulating 
cellular function.2,26-29 For example, internalized fluorescent ceramides are rapidly detected in 
mitochondria,29 where ceramide is catabolized to bioactive metabolites that promote the 
mitochondrial pathway of apoptosis.27 Figure 2.5A demonstrates that the fluorescent 
sphingolipid analogs were colocalized with the mitochondria marker, CellLight® mitochondria-
GFP, in transfected HEK293 cells that were pulse labeled with BODIPY 540 sphingosine for 30 
min and then chased for 30 min in unlabeled medium. Consistent with previous reports,29 
colocalization was not observed after the 1 day chase. Sphingolipids also perform regulatory 
and structural functions in the nucleus, but their presence and distribution in subnuclear 
compartments have primarily been identified by biochemical analysis of nuclear extracts.2 To 
assess whether the BODIPY 540 sphingosine or its BODIPY 540 labeled metabolites could be 
detected in the nucleus, we performed colocalization studies between the DNA label, Hoechst 
33342, and BODIPY 540 in labeled NIH3T3 mouse fibroblast cells. After labeling the DNA with 
Hoechst 33342, the cells were pulse labeled for 30 min with BODIPY 540 sphingosine, followed 
by a chase in unlabeled medium for approximately 2 days. From the en face confocal 
microscopy image acquired with the plane of focus at approximately the center of the cell 
(Figure 2.6A, D), small amounts of the BODIPY 540 fluorophore appeared to be in close 
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proximity to a DNA segment in the nucleus. The reconstructed cross-sectional z-stack images 
acquired along (Figure 2.6B, E) and perpendicular to (Figure 2.6C, F) the DNA segment also 
indicate that the BODIPY 540 fluorophore was inside the nucleus and adjacent to the DNA 
segment. Based on the previously reported finding that sphingomyelin is associated with 
chromatin,30 the BODIPY 540-labeled molecule associated with the DNA segment is likely 
BODIPY 540 sphingomyelin. To our knowledge, this is the first time that a fluorescent 
sphingolipid has been detected in the nucleus of a living cell. 
2.3.4 Comparison of BODIPY 540 sphingosine metabolites with BODIPY sphingosine 
metabolites 
Lastly, we compared the metabolic products of BODIPY sphingosine, a fluorescent 
sphingosine that was previously reported,8 and BODIPY 540 sphingosine. For this, NIH3T3 
mouse fibroblast cells were incubated in the medium that contained 0.75 μM of both fluorescent 
sphingosines for 1 day, and the total lipids and the sphingolipids were extracted and separated 
by TLC. The fluorescent lipids were visualized by a fluorescence imager using two different 
lasers serially (a 532nm laser for BODIPY 540 and then a 488 nm laser for BODIPY) and 
corresponding emission filters. The overlapped images of BODIPY metabolites and BODIPY 
540 metabolites in the total lipid separation (Figure 2.7) showed three spots in common, a 
couple spots that were unique to BODIPY 540 metabolites, and three spots that were unique to 
BODIPY metabolites. Comparison of the total lipids with base hydrolyzed lipids (sphingolipids) 
revealed that the most of the BODIPY 540 metabolites were glycerophospholipids and the 
majority of the BODIPY metabolites were sphingolipids. Thus, in the presence of both labeled 
sphingosines, the NIH3T3 mouse fibroblasts preferentially used BODIPY sphingosine for 
sphingolipid synthesis, and degraded the BODIPY 540 sphingosine, producing BODIPY 540-
labeled fatty acids that were incorporated into glycerolipids. 
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2.4 DISCUSSION 
We have verified the efficacy of a new fluorescent sphingosine analog, BODIPY 540 
sphingosine, for studying the transport, distribution, and metabolism of sphingolipids within living 
cells. BODIPY 540 sphingosine enabled imaging unacylated sphingolipids, which cannot be 
accomplished with the existing sphingolipid analogs that contain a fluorescent fatty acid side 
chain. Furthermore, unlike previously reported fluorescent sphingosine analogs,7-9 BODIPY 540 
sphingosine can be visualized in parallel with GFP without the use of UV excitation. By 
exploiting these capabilities, we verified that mammalian cells rapidly internalized BODIPY 540 
sphingosine, transported it to the secretory pathway where it was metabolized to more complex 
fluorescent sphingolipids, and eventually catabolized these fluorescent sphingolipids. The 
similarity in the pattern of BODIPY 540 sphingosine metabolites and their subcellular distribution 
to those of the native sphingolipids indicates that the fluorophore did not significantly hinder lipid 
metabolism or trafficking. 
Our finding that BODIPY 540 sphingosine and its metabolites mimicked the analogous 
native species in living cells is advantageous for using this probe to study dynamic sphingolipid 
processes but also has implications for its usage. Sphingosine is a bioactive signaling molecule, 
so consideration must be given to the biological effects that may be induced by labeling with the 
fluorescent analog. The BODIPY 540 sphingosine concentrations used in this work were 
substantially higher than the sphingosine concentrations found in human or bovine serum (~20 
nM).31,32 However, NIH3T3 mouse fibroblast cells did not exhibit the changes in morphology or 
growth rate that are characteristic of sphingosine toxicity during or after BODIPY 540 
sphingosine labeling.33 HEK293 cells were more sensitive to the exogenous sphingosine 
analog; changes in their morphology occurred during pulse labeling but subsided shortly after 
transfer to unlabeled chase medium. Previous reports have shown that the effects of exogenous 
sphingosine depend on the dose per cell and the capacity of the cells to metabolize it,33 so the 
adverse effects of labeling sensitive cell lines might be reduced by decreasing the BODIPY 540 
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sphingosine concentration. Alternatively, for labeling more sensitive cell lines, BODIPY 540 
sphingosine may need to be synthetically converted to BODIPY 540 sphingomyelin,34,35 which 
would have lower bioactivity1 and permit visualizing acylated and unacylated sphingolipids in 
parallel with GFP. 
The catabolic capacity of the cells to degrade the BODIPY 540 sphingolipids in a 
manner consistent with the native sphingolipid catabolism pathway, which resulted in 
fluorophore incorporation into glycerophospholipid species, also has implications for use of 
BODIPY 540 sphingosine. This property permits observing the entire sphingolipid catabolism 
pathway, which could shed light on the cellular mechanisms that underlie sphingolipid 
homeostasis. However, this catabolism complicates the use of BODIPY 540 sphingosine to 
visualize the subcellular sphingolipid distribution selectively because some of the fluorescence 
observed will be produced by glycerolipids. The same problem is encountered with fluorescent 
sphingolipid analogs that contain a fluorophore-labeled N-acyl fatty acid because they are also 
catabolized to fluorescent fatty acids that are incorporated into glycerolipids.5 We observed that 
the incorporation of BODIPY 540 into glycerolipids increased with increasing labeling time, so 
the fluorescence from nonsphingolipid species can be minimized by limiting the labeling time. In 
addition, the presence of a second fluorescent sphingosine analog, BODIPY sphingosine, in the 
medium increased the incorporation of BODIPY 540 into glycerolipids. The irreversible 
degradation of sphingosine-1-phosphate to fatty acid precursors, which causes the label 
scrambling we observed, has been shown to increase with increasing sphingosine 
concentration in the medium.20,33 Thus, eliminating the presence of other sphingosine analogs 
and decreasing the BODIPY 540 sphingosine concentration in the labeling media should reduce 
fluorophore incorporation into glycerolipid species.  
Interestingly, more sphingolipids were produced from BODIPY sphingosine than 
BODIPY 540 sphingosine, whereas the opposite was true for the glycerophospholipids when 
NIH3T3 mouse fibroblast cells were simultaneously labeled with both fluorescent sphingosine 
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analogs. The different fates of these two fluorescent sphingosine analogs may reflect 
differences in substrate preferences between the different enzymes that metabolize 
sphingosine. Sphingosine can be N-acylated by ceramide synthases to produce ceramides and 
further metabolized to complex sphingolipids, or phosphorylated by sphingosine kinases to 
produce S1P, which is catabolized to a fatty aldehyde that can be eventually incorporated into 
glycerophospholipids.16 The finding that more sphingomyelin and glycosphingolipids contained 
the BODIPY fluorophore suggests that the ceramide synthases in the mouse fibroblasts 
preferred BODIPY sphingosine to BODIPY 540 sphingosine as a substrate. Because BODIPY 
540 sphingosine is longer and has larger fluorophore than BODIPY sphingosine, these findings 
may suggest that ceramide synthases require tighter coordination to the hydrophobic tail of the 
sphingosine substrate than sphingosine kinase. Of course, in vitro rate measurements would 
need to be performed to confirm the substrate specificities of ceramide synthases and 
sphingosine kinase for these two fluorescent sphingolipid analogs, and subsequent studies 
would be required to determine how substrate structure affects this selectivity. Nonetheless, the 
different preferences of the sphingolipid metabolic enzymes for BODIPY sphingosine and 
BODIPY 540 sphingosine may be useful as selective substrates for determining the activities of 
the two different sphingosine processing enzymes.  
The ability to track unacylated sphingolipid analogs with BODIPY 540 sphingosine opens 
the door to identifying the subcellular locations where these bioactive molecules encounter their 
targets. One such unacylated sphingolipid, sphingosine-1-phosphate, stimulates signaling by 
binding to G protein-coupled receptors on the cell surface.1,18 Recently, the hypothesis that 
fundamental cellular processes are regulated by sphingosine-1-phosphate binding to 
intracellular targets was verified. Specifically, sphingosine-1-phosphate binding to histone 
deacetylases in the nucleus regulates gene transcription,28 whereas its binding to the pro-
apoptotic effector molecule, BAK, in mitochondria promotes apoptosis.27 In both cases, the 
sphingosine-1-phosphate was generated in the organelle where its target resided, and this 
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location determined the effects of this binding on cell function. Efforts to identify additional 
intracellular targets of unacylated sphingolipids and their mechanisms of action may be 
facilitated by visualizing the subcellular distributions of BODIPY 540 sphingosine metabolites 
and GFP-labeled sphingolipid metabolizing enzymes in parallel. 
The detection of BODIPY 540 sphingosine metabolites associated with DNA in the 
nucleus demonstrates the potential to discover new phenomena by metabolic labeling with 
BODIPY 540 sphingosine. To our knowledge, this is the first observation of fluorescent 
sphingosine metabolite association with DNA in the nucleus of a living cell, although further 
studies are required to confirm the BODIPY 540 labeled molecule was BODIPY 540 
sphingomyelin. Since their detection in the nucleus decades ago,36,37 the identities and 
subnuclear distributions of sphingolipids have been primarily probed by biochemical analysis of 
isolated nuclei and visualization of sphingolipid-specific functionalized affinity labels.2,38,39 
Additionally, structural and regulatory roles performed by various types of sphingolipids in the 
nucleus have been identified.2 Sphingomyelin associates with chromatin and stabilizes DNA and 
newly synthesized RNA,39,40 GM1 regulates nuclear calcium concentrations,38 and nuclear 
ceramide is involved in proliferation and apoptosis, although the precise mechanisms remain to 
be established.41-43 As mentioned above, nuclear sphingosine-1-phosphate regulates gene 
expression by binding to histone deacetylases, thereby inhibiting histone deacetylation.28 
Despite these discoveries, many aspects of nuclear sphingolipid function remain poorly 
understood. BODIPY 540 sphingosine may potentially be used to visualize nuclear 
sphingolipids, which may allow for a better understanding of how various stimuli influence 
nuclear sphingolipid distribution and the consequences for cell function. 
BODIPY 540 sphingosine can be used to monitor the trafficking and metabolism of 
acylated and unacylated sphingolipids in living cells. Assessment of colocalization between 
BODIPY 540 sphingolipids and with GFP-labeled proteins of interest will facilitate identifying the 
subcellular locations where sphingolipids are metabolized or encounter their binding targets. 
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Such studies can provide new insight into the broad roles of sphingolipids in modulating cellular 
function. 
 
2.5 REFERENCES 
1 Y. A. Hannun & L. M. Obeid. Principles of bioactive lipid signalling: lessons from 
sphingolipids. Nat. Rev. Mol. Cell Biol. 9, 139-150 (2008). 
2 N. C. Lucki & M. B. Sewer. Nuclear sphingolipid metabolism. Annu. Rev. Physiol. 74, 
131-151 (2012). 
3 T. Kolter. A view on sphingolipids and disease. Chem. Phys. Lipids 164, 590-606 (2011). 
4 T. Kolter & K. Sandhoff. Sphingolipid metabolism diseases. Biochim. Biophys. Acta 
1758, 2057-2079 (2006). 
5 J.-a. M. Rasmussen & A. Hermetter. Chemical synthesis of fluorescent glycero-and 
sphingolipids. Prog. Lipid Res. 47, 436-460 (2008). 
6 L. Kuerschner, C. S. Ejsing, K. Ekroos, A. Shevchenko, K. I. Anderson & C. Thiele. 
Polyene-lipids: a new tool to image lipids. Nat. Methods 2, 39-45 (2005). 
7 P. Ettmayer, A. Billich, T. Baumruker, D. Mechtcheriakova, H. Schmid & P. Nussbaumer. 
Fluorescence-labeled sphingosines as substrates of sphingosine kinases 1 and 2. Biorg. 
Med. Chem. Lett. 14, 1555-1558 (2004). 
8 C. Peters, A. Billich, M. Ghobrial, K. Högenauer, T. Ullrich & P. Nussbaumer. Synthesis 
of borondipyrromethene (BODIPY)-labeled sphingosine derivatives by cross-metathesis 
reaction. J. Org. Chem. 72, 1842-1845 (2007). 
9 T. Hakogi, T. Shigenari, S. Katsumura, T. Sano, T. Kohno & Y. Igarashi. Synthesis of 
fluorescence-labeled sphingosine and sphingosine 1-phosphate; effective tools for 
sphingosine and sphingosine 1-phosphate behavior. Biorg. Med. Chem. Lett. 13, 661-
664 (2003). 
10 C. Bode et al. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 
1-phosphate. J. Cell. Biochem. 109, 1232-1243 (2010). 
11 E. L. Snapp. Fluorescent proteins: a cell biologist's user guide. Trends Cell Biol. 19, 649-
655 (2009). 
12 R. Kim, K. Lou & M. L. Kraft. A new, long-wavelength borondipyrromethene sphingosine 
for studying sphingolipid dynamics in live cells. J. Lipid Res. 54, 265-275 (2013). 
13 W. J. D. E. G. Bligh. A rapid method of total lipid extraction and purification. Can. J. 
Biochem. Physiol. 37, 911-917, doi:10.1139/o59-099 (1959). 
14 G. K. Voeltz, W. A. Prinz, Y. Shibata, J. M. Rist & T. A. Rapoport. A class of membrane 
proteins shaping the tubular endoplasmic reticulum. Cell 124, 573-586 (2006). 
15 M. C. Sullards & A. H. Merrill. Analysis of sphingosine 1-phosphate, ceramides, and 
other bioactive sphingolipids by high-performance liquid chromatography-tandem mass 
spectrometry. Sci. STKE 2001, pl1 (2001). 
16 K. Nakahara et al. The Sjögren-Larsson syndrome gene encodes a hexadecenal 
dehydrogenase of the sphingosine 1-phosphate degradation pathway. Mol. Cell 46, 461-
471 (2012). 
17 P. P. Van Veldhoven & G. P. Mannaerts. Subcellular localization and membrane 
topology of sphingosine-1-phosphate lyase in rat liver. J. Biol. Chem. 266, 12502-12507 
(1991). 
18 M. Maceyka, S. Milstien & S. Spiegel. Sphingosine-1-phosphate: the Swiss army knife of 
sphingolipid signaling. J. Lipid Res. 50, S272-S276 (2009). 
		27 
19 W. Stoffel & G. Sticht. Metabolism of sphingosine bases, II. Studies on the degradation 
and transformation of [3-14C]erythro-DL-dihydrosphingosine,[7-3H]erythro-DL-
sphingosine,[5-3H]threo-L-dihydrosphingosine and [3-14C;1-3H]erythro-DL-
dihydrosphingosine in rat liver. Hoppe Seylers Z. Physiol. Chem. 348, 1345-1351 (1967). 
20 L. Riboni, R. Bassi, A. Prinetti, P. Viani & G. Tettamanti. Predominance of the acylation 
route in the metabolic processing of exogenous sphingosine in neural and extraneural 
cells in culture. Biochem. J 338, 147-151 (1999). 
21 N. Bartke & Y. A. Hannun. Bioactive sphingolipids: metabolism and function. J. Lipid 
Res. 50, S91-S96 (2009). 
22 T. Kolter & K. Sandhoff. Lysosomal degradation of membrane lipids. FEBS Lett. 584, 
1700-1712 (2010). 
23 H. Schulze, T. Kolter & K. Sandhoff. Principles of lysosomal membrane degradation: 
Cellular topology and biochemistry of lysosomal lipid degradation. Biochim. Biophys. 
Acta 1793, 674-683 (2009). 
24 K. Kitatani, J. Idkowiak-Baldys & Y. A. Hannun. The sphingolipid salvage pathway in 
ceramide metabolism and signaling. Cell. Signal. 20, 1010-1018 (2008). 
25 S. L. Schmid, R. Fuchs, P. Male & I. Mellman. Two distinct subpopulations of 
endosomes involved in membrane recycling and transport to lysosomes. Cell 52, 73-83 
(1988). 
26 D. Ardail et al. Occurrence of ceramides and neutral glycolipids with unusual long-chain 
base composition in purified rat liver mitochondria. FEBS Lett. 488, 160-164 (2001). 
27 J. E. Chipuk et al. Sphingolipid metabolism cooperates with BAK and BAX to promote 
the mitochondrial pathway of apoptosis. Cell 148, 988-1000 (2012). 
28 N. C. Hait et al. Regulation of histone acetylation in the nucleus by sphingosine-1-
phosphate. Science 325, 1254-1257 (2009). 
29 N. G. Lipsky & R. E. Pagano. Intracellular translocation of fluorescent sphingolipids in 
cultured fibroblasts: endogenously synthesized sphingomyelin and glucocerebroside 
analogues pass through the Golgi apparatus en route to the plasma membrane. J. Cell 
Biol. 100, 27-34 (1985). 
30 C. Scassellati et al. Intranuclear sphingomyelin is associated with transcriptionally active 
chromatin and plays a role in nuclear integrity. Biol. Cell 102, 361-375 (2010). 
31 S. Ribar, M. Mesarić & M. Bauman. High-performance liquid chromatographic 
determination of sphinganine and sphingosine in serum and urine of subjects from an 
endemic nephropathy area in Croatia. J. Chromatogr. B Biomed. Sci. Appl. 754, 511-519 
(2001). 
32 S. Mathur et al. Fumonisin B1 increases serum sphinganine concentration but does not 
alter serum sphingosine concentration or induce cardiovascular changes in milk-fed 
calves. Toxicol. Sci. 60, 379-384 (2001). 
33 L. Riboni, A. Prinetti, R. Bassi, P. Viani & G. Tettamanti. The effects of exogenous 
sphingosine on Neuro2a cells are strictly related to the overall capacity of cells to 
metabolize sphingosine. J. Biochem. 124, 900-904 (1998). 
34 T. Y. Ahmad, J. T. Sparrow & J. D. Morrisett. Fluorine-, pyrene-, and nitroxide-labeled 
sphingomyelin: semi-synthesis and thermotropic properties. J. Lipid Res. 26, 1160-1165 
(1985). 
35 H.-S. Byun, R. K. Erukulla & R. Bittman. Synthesis of sphingomyelin and ceramide 1-
phosphate from ceramide without protection of the allylic hydroxyl group. J. Org. Chem. 
59, 6495-6498 (1994). 
36 F. A. Manzoli, N. M. Maraldi, L. Cocco, S. Capitani & A. Facchini. Chromatin 
phospholipids in normal and chronic lymphocytic leukemia lymphocytes. Cancer Res. 
37, 843-849 (1977). 
		28 
37 L. Cocco, N. M. Maraldi, F. A. Manzoli, R. S. Gilmour & A. Lang. Phospholipid 
interactions in rat liver nuclear matrix. Biochem. Biophys. Res. Commun. 96, 890-898 
(1980). 
38 R. W. Ledeen & G. Wu. Gangliosides of the nuclear membrane: a crucial locus of 
cytoprotective modulation. J. Cell. Biochem. 97, 893-903 (2006). 
39 E. Albi & M. Magni. The role of intranuclear lipids. Biol. Cell 96, 657-667 (2004). 
40 M. Micheli, E. Albi, C. Leray & M. V. Magni. Nuclear sphingomyelin protects RNA from 
RNase action. FEBS Lett. 431, 443-447 (1998). 
41 E. Albi, S. Cataldi, G. Rossi, M. V. Magni, M. Toller, S. Casani & G. Perrella. The nuclear 
ceramide/diacylglycerol balance depends on the physiological state of thyroid cells and 
changes during UV-C radiation-induced apoptosis. Arch. Biochem. Biophys. 478, 52-58 
(2008). 
42 M. Watanabe et al. Increase of nuclear ceramide through caspase-3-dependent 
regulation of the “sphingomyelin cycle” in Fas-induced apoptosis. Cancer Res. 64, 1000-
1007 (2004). 
43 K. Tsugane, K. Tamiya-Koizumi, M. Nagino, Y. Nimura & S. Yoshida. A possible role of 
nuclear ceramide and sphingosine in hepatocyte apoptosis in rat liver. J. Hepatol. 31, 8-
17 (1999). 
 
		29 
2.6 FIGURES 
 
 
 
 
 
Figure 2.1. Absorbance and emission spectra of BODIPY 540 sphingosine in ethanol. The 
emission spectrum was collected using a 488 nm excitation. 
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Figure 2.2. Subcellular distribution and metabolism of BODIPY 540 sphingosine in NIH3T3 
mouse fibroblast cells. Cells were incubated in 1.25 μM of BODIPY 540 sphingosine for 30 min 
followed by unlabeled medium for a chase time of 30 min (A) or 20 h (B). Bars = 20 μm. 
Although the plasma membrane of the cell shown in B is dim in comparison to the highly 
fluorescent intracellular vesicles that were especially abundant in the NIH3T3 mouse fibroblast 
cells we examined, the more distinct fluorescent outline at the edge of the cell indicates that 
BODIPY 540 lipids were present in the plasma membrane. C: Lipid fractions were isolated from 
cells that were labeled with 1 μM of BODIPY 540 sphingosine for 2 h or 1 day. The total lipid 
fractions (−) and the lipid fractions subjected to alkaline treatment to remove the glycerolipids (+) 
were separated by TLC, as described in the Materials and Methods. Images were taken on a 
fluorescence imager using a 532 nm laser for excitation and a 580 nm emission filter. The 
identities of the BODIPY 540-labeled species that are indicated to the right of each spot were 
determined by comparison to lipid standards (see Materials and Methods for details). Cer, 
ceramide; FA, fatty acids; GluCer, glucosylceramide; LacCer, lactosylceramide; PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, 
phosphatidylserine; SM, sphingomyelin; Sph, sphingosine 
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Figure 2.3. Intracellular distribution of BODIPY 540 sphingosine and its fluorescent metabolites. 
Transfected HEK293 cells that expressed GFP-Sec61β or CellLight® Golgi-GFP were pulse 
labeled for 30 min in medium containing 1 μM of BODIPY 540 sphingosine and transferred to 
unlabeled medium for the chase time indicated to the right of the last column. Confocal 
microscopy imaging was performed on living cells at room temperature. The GFP signal (green) 
locates the ER (A and C) or Golgi apparatus (B and D). The BODIPY 540 signal (red) shows the 
subcellular distribution of BODIPY 540 sphingosine and its fluorescent metabolites. The 
fluorescent outline of each cell, which signifies the incorporation of BODIPY 540 lipids into the 
plasma membrane, is especially distinct in these images because these HEK293 cells have few 
highly fluorescent intracellular vesicles. The overlay images show that colocalization between 
BODIPY 540 and each organelle-specific GPF fusion protein (yellow) occurred when the chase 
time was 30 min (A and B) but not 1 day (C and D). Bars = 20 μm. 
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Figure 2.4. Localization of BODIPY 540 sphingolipid analogs in lysosomes. The lysosomes in 
NIH3T3 mouse fibroblast cells were labeled by incubating the cells for 30 min in medium 
containing 2 mg/mL of FITC-dextran and then transferring the cells to label-free medium for 5 h. 
The lysosome-labeled NIH3T3 mouse fibroblast cells were incubated for 30 min in culture 
medium containing 1 μM of BODIPY 540 sphingosine and transferred to label-free medium for 
the chase time indicated to the right of the last column. Confocal imaging of the living cells at 
room temperature revealed the intracellular distribution of the FITC-dextran (green) that labeled 
the lysosomes and BODIPY 540 sphingosine and its metabolites (red). The overlay images (last 
column) show that colocalization between BODIPY 540 and FITC-dextran (yellow) did not occur 
after a 30 min chase but was detectable at low levels after a 16 h chase. Bars = 20 μm. 
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Figure 2.5. Transfected HEK293 cells that expressed CellLight® mitochondria-GFP were pulse 
labeled for 30 min in medium containing 1 μM of BODIPY 540 sphingosine and transferred to 
unlabeled medium for 30 min (A) or 1 day (B). The locations of the mitochondria (green) and 
BODIPY 540 sphingolipid analogs (red) were imaged in living cells at room temperature with 
confocal microscopy. The overlay images (last column) show that a high amount of 
colocalization (yellow) occurred between BODIPY 540 and CellLight® mitochondria-GFP 30 min 
after pulse labeling. In contrast, colocalization of the two fluorescent components was not 
detected when the chase time increased to 1 day. Bars = 20 μm. 
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Figure 2.6. Detection of BODIPY 540 sphingosine metabolites in the nucleus. The DNA in 
NIH3T3 mouse fibroblast cells was labeled with Hoechst 33342 for 30 min. After 30 min in 
unlabeled medium, the cells were pulse labeled for 30 min with BODIPY 540 sphingosine and 
chased in unlabeled medium for approximately 2 days. Confocal imaging of the cell shows the 
subcellular location of DNA (blue) and BODIPY 540 sphingolipid analogs (red). A: An en face 
confocal microscopy image acquired with the plane of focus at approximately the center of the 
cell. The horizontal and vertical white dashed lines denote where cross-sectional images were 
acquired. B: Reconstructed cross-section acquired at the vertical white dashed line shown in A. 
z-scan step: 0.2 μm. C: Reconstructed cross-section acquired at the horizontal white dashed 
line shown in A. z-scan step: 0.2 μm. D: Enlargement of the region outlined in yellow in A. E: 
Enlargement of the region outlined in yellow in B. F: Enlargement of the region outlined in yellow 
in C. Bars in E and F = 1 μm. 
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Figure 2.7. Cellular metabolism of BODIPY 540 sphingosine produces more glycerolipids than 
BODIPY sphingosine metabolism in the cells. NIH3T3 mouse fibroblast cells were incubated 
with 0.75 µM each of BODIPY sphingosine and BODIPY 540 sphingosine for 1 day. The cellular 
lipids were extracted and separated by TLC either with or without base hydrolysis, as described 
in the Materials and Methods. The fluorescent lipids that were separated on the TLC plate were 
imaged using a fluorescence imager with a 532 nm laser for excitation and a 580 nm emission 
filter for BODIPY 540 (C), and a 488 nm laser for excitation and a 520 nm emission filter for 
BODIPY (B). A: overlapped images of BODIPY lipids and BODIPY 540 lipids. B: BODIPY lipids, 
C: BODIPY 540 lipids.   
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CHAPTER 3 
STABLE ISOTOPE METABOLIC LABELING AS A TOOL  
TO STUDY SPHINGOLIPID METABOLISM* 
 
3.1 INTRODUCTION 
Metabolic pathways of sphingolipids are well established despite their complexity. 
However, we are still far from a complete view of sphingolipid metabolism and behavior. For 
instance, the generation of ceramides by two different pathways, the de novo pathway and 
sphingomyelinase-dependent pathway, is well established but the contribution of each of these 
metabolic pathways to total ceramide synthesis is not known. This issue becomes more difficult 
and complicated if subcellular locations are also considered in parallel with sphingolipid 
metabolism, especially because the kinetics of each sphingolipid metabolic reaction are not well 
known. Considering the significance of sphingolipids in cell signaling and pathological 
conditions, these questions must be addressed in order to further understand and control 
sphingolipid behaviors for therapeutic interventions. For this purpose, measurements must be 
directly performed on the sphingolipids, and not the activities or expression levels of the 
enzymes that produce them, which, until recently, has not been possible.  
Radioactive labeling has been the major tool for understanding sphingolipid metabolism 
and kinetics. Radiolabels, such as [3H] or [14C], have been incorporated into sphingosine and 
sphingolipids, as well as serine,1 which is a substrate for de novo ceramide synthesis, in order 
to study sphingolipids. [14C] radiolabeling has also been used to investigate sphingomyelin 
																																																						*	 I thank A. Ulanov and Z. Li at the Metabolomics Center for technical assistance on lipidomics 
study and lipid analysis with LC-MS and LC-MS/MS, and Dr. Kaiyan Lou for the synthesis of 
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Biotechnology Center at the University of Illinois at Urbana-Champaign.  	
		37 
synthesis.2 These radioactive labels are incorporated into sphingolipids or phospholipids, 
producing radioactive sphingolipids following sphingolipid metabolism. Many studies on 
sphingolipid metabolism have been performed by detecting the only the radiolabeled lipids with 
thin film chromatography and autoradiography. The high sensitivity of radiolabel detection 
enables studying the metabolism of even minor lipid species, but such radiolabeling studies do 
not provide any information about the unlabeled lipids.    
Stable isotope labeling has been also used, though less frequently, to study sphingolipid 
metabolism.3 Since labeled lipids are analyzed using mass spectrometry, whether performed 
with or without chromatographic separation, the sensitivity and mass resolution of mass 
spectrometry has been the limiting factor for using stable isotope labeling for lipid metabolism 
research. Mass isotopomer distribution analysis (MIDA) has been developed for measuring the 
synthesis of lipids as well as carbohydrates and proteins.4 Cholesterol and fatty acid synthesis 
was investigated using 13C-acetate and MIDA,5 but improvements in the mass spectrometer’s 
analytic performance was still required.6 To overcome these limitations in instrumentation and 
ensure the detection of labeled sphingolipid species, substrates that contain multiple stable 
isotope labels such as [U-13C, 15N] serine,7 D9-choline,8 or 13C-palmitate9 have been employed. 
A possible drawback of this multi-label approach is that the incorporation of the labels into 
sphingolipids can be low because the labeled substrates are also metabolized into other 
species. Stable-isotope labeled sphingoid backbones, sphingosine and sphinganine, would 
circumvent this issue and improve incorporation efficiency because, unlike serine, choline, or 
palmitate, the sphingoid backbones are metabolized mostly to sphingolipids. However, the use 
of stable-isotope labeled sphingoid bases for sphingolipid metabolism studies has not been 
reported yet due to the lack of commercially available sphingolipid backbones that are labeled 
with stable isotopes, and perhaps also due to the limited ability of mass spectrometers suitable 
for analyzing metabolic products.   
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Recent improvement in mass spectrometry enables distinguishing lipid species with 
mass differences less than 1 Da, opening tremendous opportunities for lipid research. A 
lipidomics approach, an -omics approach analogous to genomics and proteomics, is already 
gaining attention from the scientific community, and has demonstrated the capability of 
obtaining comprehensive and meaningful data on lipids. For instance, differences in lipid 
composition before and after epithelial-to-mesenchymal transition was characterized using a 
shotgun lipidomics analysis.10 The same group also reported the quantitative lipidomics analysis 
of the lipids in the influenza viral envelope and the host cells,11 which revealed the influenza 
virus envelope contained more sphingolipids and cholesterol than the donor cell membrane. 
However, lipidomics approaches that do not employ any isotope labels are unable to answer 
questions concerning the dynamics or kinetics of lipid metabolism.  
Here I set out to use stable isotope labeled sphingoid bases to metabolically label 
sphingolipids in cells. Prior to metabolic labeling, the sphingolipids of unlabeled NIH3T3 mouse 
fibroblast cells were profiled by lipidomics analysis using LC-MS/MS. Then, NIH3T3 mouse 
fibroblast cells were metabolically labeled with 15N-sphingoid bases and 13C-fatty acids, which 
were incorporated into their cellular sphingolipids, for various time intervals. The resulting 
cellular lipids were analyzed with LC-MS or LC-MS/MS to assess the production of stable 
isotope-labeled sphingolipids as a function of labeling time. This study indicates that stable 
isotope labeling in combination with the improved mass spectrometry can be a powerful tool for 
lipid metabolism research that exploits both the label’s specificity and the comprehensive 
dataset produced by lipidomics analysis. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
15N-sphingosine and 15N-sphinganine were synthesized as previously reported.12 13C-
algal lipid mix was purchased from Cambridge Isotope Laboratories, Inc. (Tewksbury, MA). 
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13C18-stearic acid (99% atom% 13C) and defatted bovine serum albumin (BSA) was purchased 
from Sigma-Aldrich (Saint Louis, MO).  
3.2.2 Cell culture 
NIH3T3 mouse fibroblast cells (ATCC CRL-1658TM) were grown in Dulbecco's Modified 
Eagle Medium (DMEM) supplemented with calf serum (10% final concentration in medium) and 
penicillin/streptomycin (1%) at 37°C in 5% CO2.  
3.2.3 Preparation of 14N-sphingoid base, 15N-sphingoid base, and 13C-fatty acid stock 
solutions 
Unlabeled (natural abundance) sphingoid bases, referred to as 14N-sphingoid bases, and 
15N-sphingoid bases were each separately dissolved in DMSO to make separate 6 mM stock 
solutions. The stock solutions were filtered through a sterile 0.2 μm PTFE syringe filter unit, 
aliquoted and stored at -20°C. 13C-fatty acid mixture were prepared as previously described13 by 
dissolving 13.3 mg of 13C-algal lipid mix and 3.3 mg 13C-stearic acid in 750 μL DMSO followed 
by filtering through a 0.2 µm PTFE syringe filter unit. Then the 13C-fatty acids in DMSO were 
complexed with 250 μL of 125 mg/mL filtered defatted BSA for efficient delivery to the cells. The 
resulting solution was vortexed, sonicated for 10-15 min, and then stored at 4°C until labeling 
(up to a week). When used, the solution was warmed, vortexed, and sonicated for 10-15 min 
prior to use. The concentration of this 13C stock solution is 16.6 mg/mL or approximately 55.6 
mM.13  
3.2.4 Metabolic Labeling 
The cells were seeded in a 100 mm dish with 10 mL of the normal growth media. As a 
pre-labeling step, 14N-sphingoid bases were added to the cell culture media to produce a final 
concentration of 3 μM on a daily basis for 2 days. On the third day, the medium was exchanged 
for fresh growth medium that contained the same concentration (3 μM) of 14N-sphingoid bases. 
For the labeling step, labeling media were prepared by adding stock solutions of 15N-sphingoid 
bases and 13C-fatty acids in DMEM supplemented with 1% calf serum (final concentration) and 
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10% charcoal stripped FBS (Gibco). The final concentrations of 15N-sphingoid bases and 13C-
fatty acids in the labeling media were 3 μM and 215 μM respectively. The cells were washed 
with DPBS and then were cultured in the labeling media for various time intervals. After the 
labeling, the cells were detached from the dishes using trypsin/EDTA, pelleted by centrifugation, 
washed with DPBS, and stored as pellets at -20°C.  
3.2.5 Lipid extraction 
Cellular lipids were extracted following Bligh and Dyer method with slight modification14 
as described previously.13 The pelleted cells were suspended in 0.75 mL of water  (the residual 
water in the pellet makes up approximately to 0.8 mL). Then 2 mL of methanol and 1 mL of 
chloroform were added to the mixture, and the solution was vortexed thoroughly, sonicated for 
30-60 sec, and then allowed to sit for several hours at room temperature. The resulting solution 
was centrifuged at 1,811 g for 5 min. The supernatant was decanted into a new glass vial, 1 mL 
of chloroform and 1 mL of water was added, and the solution was vortexed hard. Centrifugation 
at 1,811g for 5 min resulted in a biphasic solution. The lower chloroform layer was collected, 
transferred into a new glass vial, and dried under nitrogen gas stream. The resulting lipids were 
stored at -20°C until LC-MS analysis.  
3.2.6 LC-MS analysis 
The extracted cellular lipids were analyzed using Thermo Q-Exactive hybrid quadruple 
Orbitrap mass spectrometer after separation with an Ultimate 3000 HPLC system. Separation 
was performed either with a Phenomenex Gemini 3u C6-Phenyl 110A column (2 × 100 mm) 
using methanol at a flow rate of 300 μL/min, or a Thermo Accucore C18 LC column (2.1 × 150 
mm) using two mobile phases (mobile phase A: 60% ACN, 10 mM ammonia formate, 0.1% 
formic acid, mobile phasee B: 90% isopropanol, 10% acetonitrile, 10 mM ammonia formate, 
0.1% formic acid) in gradient at a flow rate of 400 μL/min. The m/z was scanned in the range of 
230-1600. The resolution of the mass spectrometry (R) was 70,000. For lipidomics analysis of 
the cellular sphingolipids from unlabeled NIH3T3 mouse fibroblast cells, the resulting LC-
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MS/MS data of the unlabeled cellular lipids were analyzed by LipidSearch (Thermo Fisher 
Scientific). The amount of each species was measured by first identifying the retention time for 
C16-SM and C16-ceramide, and then obtaining the mass peak intensity of corresponding m/z 
values at the retention time.  
 
3.3 RESULTS 
3.3.1 Profiling sphingolipids in NIH3T3 murine fibroblast cellular lipids 
Cellular sphingolipids extracted from unlabeled NIH3T3 mouse fibroblast were first 
profiled. Lipidomics analysis revealed that palmitoyl sphingomyelin (C16-SM) was the dominant 
sphingolipid species in NIH3T3 mouse fibroblasts (Figure 3.1 and Table 3.1). The level of C16-
SM was about 10 times higher than the second most abundant sphingolipid, C16-
glucosylceramide. This lipidomics analysis indicates that palmitic acid or palmitoyl CoA is the 
most favorable substrate for N-acylation of the sphingoid base for sphingolipid production in 
NIH3T3 mouse fibroblast cells. Therefore, the subsequent metabolic labeling analysis focused 
on C16-SM and its upstream lipid species, C16-ceramide.  
3.3.2 Detection and identification of labeled sphingolipids 
The cells were labeled with 6 μM of 15N-sphingoid bases and 215 µM of 13C-fatty acids 
for various time after pre-labeling the cells with 3 μM of 14N-sphingid bases for 3 days. Pre-
labeling was performed to ensure that the cells would be able to process the relatively high 
levels of exogenous sphingoid bases. Metabolic labeling with 15N-sphingoid bases and 13C-fatty 
acids permitted the incorporation of two different rare stable isotopes, 15N and 13C, into the 
cellular sphingolipids’ sphingoid backbones and fatty acyl chains, respectively.  
High-resolution mass spectrometry allowed detection of both non-labeled and 15N and 
13C-fatty acid labeled C16-SM (15N13C16 C16-SM) with mass error of less than 0.0035 from the 
calculated value. However, C16-SM labeled with either 15N-sphingoid or 13C-fatty acids showed a 
much higher mass error (0.006-0.009) from the theoretical value. We reasoned that this peak 
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with higher error was due to the presence of two unresolved peaks, one from 15N-labeled C16-
SM (15N12C16 C16-SM), and the other from C16-SM with only one 13C (14N13C1 C16-SM); the 
natural occurrence of 14N13C1 C16-SM in an unlabeled sample is 0.422 time that of 14N12C16 C16-
SM. This altered the m/z value of the peak such that it was closer to that of 14N13C1 C16-SM 
(theoretical m/z 704.5788) for short labeling periods and closer to the m/z of 15N12C16 C16-SM 
(theoretical m/z 704.5724) for longer labeling periods. Therefore, the abundance of 15N-labeled 
C16-SM was calculated by assuming that the observed mass peak consisted of two Gaussian 
peaks from the two different C16-SM, 14N13C1 C16-SM and 15N12C16 C16-SM, superimposed on top 
of one another. This assumption was also made to calculate the abundance of 14N13C16 C16-SM 
(14N13C16 C16-SM vs. 15N13C1512C1 C16-SM). C16-ceramide species were also detected in parallel 
with the C16-SM isotopologues. Again, the mass error of C16-ceramide labeled with only one of 
the two rare isotopes was higher (0.005-0.008) than unlabeled sphingomyelin and 15N13C16 C16-
SM (0.0025). Therefore, the same assumption was used to calculate the 15N12C16 C16-ceramide 
and14N13C16 C16-ceramide abundances. The list of m/z values for identifying labeled and 
unlabeled C16-ceramide and C16-SM are listed in Table 3.2.  
3.3.3 Incorporation of 15N-sphingoid and 13C-fatty acids into C16-ceramide and C16-SM 
The incorporation of 15N-sphingoid bases into C16-ceramide and C16-SM were evaluated 
and the results are shown in Figure 3.2. The incorporation of 15N-sphingoid bases into C16-
ceramide increased until it reached a maximum at some time between 4-8 hours and then 
decreased (Figure 3.2A) while incorporation into SM increased continuously with time over the 
course of the pulse labeling experiment (Figure 3.2B). These general trends of incorporation 
into ceramide and SM were similar to the results reported for radiolabeling even though the time 
point when the maximum incorporation was reached would vary depending on the concentration 
of the label and the cell types.15  
The incorporation of 13C-fatty acids into C16-ceramide and C16-SM were also determined, 
as shown in Figure 3.3. The incorporation of 13C-fatty acids into C16-ceramide increased for the 
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first 4 h, and then reached a plateau (Figure 3.3A). The incorporation of 13C-fatty acids into C16-
SM increased continuously during the 24 h labeling interval (Figure 3.3B), similar to 15N-
sphingoid incorporation into C16-SM.  
3.3.4 Comparison of labeled and total C16-ceramide and C16-SM levels  
Next, the levels of labeled and total C16-ceramide and C16-SM were compared (Figure 
3.4). SM is generated from ceramide, therefore when new SM synthesis increases, the increase 
in SM levels should be accompanied by a decrease in ceramide levels. For both the 
incorporation of 15N-sphingoid bases and 13C-fatty acids into C16-SM and C16-ceramide, the 
SM/ceramide ratio increased with labeling time (Figure 3.4A and B).  
 Prior to metabolic labeling, the cellular SM levels were significantly higher than the 
cellular ceramide levels. However, the addition of 15N-sphingoid bases would increase the total 
level of sphingoid bases in the cells, and subsequently ceramide synthesis based on the 
sphingolipid metabolic pathway, which might trigger cell cycle arrest and apoptosis16 unless the 
newly synthesized ceramide was rapidly converted to SM. Therefore, the total (labeled and 
unlabeled) SM to ceramide ratio was calculated at different labeling times. The ratio of total SM 
to ceramide rapidly decreased until it reached a minimum at 4 h of labeling (Figure 3.4C), which 
corresponds to the labeling time when the isotope-labeled ceramide levels reached a maximum, 
and then increased continuously after 8 h. 
3.3.5 The effect of 13C-fatty acid labeling on 15N-sphingoid labeling efficiency 
 Lastly, we evaluated whether the addition of 13C-fatty acids affected the efficiency of 
incorporating 15N-sphingoid bases into the cellular sphingolipids. The cells were metabolically 
labeled using only 15N-sphingoids for 4 h or 24 h, at which point the lipids were extracted and 
subjected to LC-MS. Then the incorporation of 15N-sphingoid bases into C16-ceramide in the 
absence of 13C-fatty acids was compared to the incorporation obtained when metabolic labeling 
was performed with 13C-fatty acids (Figure 3.5A). No difference in 15N-sphingoid base 
incorporation into C16-ceramide and C16-SM was detected after labeling for 4 h labeling with and 
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without 13C-fatty acids. For the 24 h labeling interval, the incorporation of 15N-sphingoid bases 
into SM was similar in the presence or absence of fatty acids, but more ceramide contained the 
15N-sphingoid bases when 13C-fatty acids were added during the labeling.  
The 15N-labeled SM/ceramide ratio and the total SM/ceramide ratios with and without 
13C-fatty acids were also compared (Figure 3.5B). After labeling for 4 h, the difference between 
the SM/ceramide ratios measured for labeling performed with and without 13C-fatty acids was 
not significant. However, after 24 h of labeling, both the 15N-labeled SM/ceramide ratio and the 
total SM/ceramide ratio were much higher when the labeling was performed without 13C-fatty 
acids.  
 
3.4 DISCUSSION 
Thanks to recent improvements in mass spectrometry, stable isotope labeling now has 
great potential as a tool that may substitute for radiolabeling for studies of lipid metabolism. A 
limited number of reported studies have employed stable isotope labeling for sphingolipid 
research thus far.7-9 Here, we used 15N-labeled sphingoid bases and 13C-fatty acids to 
selectively label sphingolipids, and confirmed the feasibility of this metabolic labeling strategy. 
Even though 15N-sphingoid bases would be an obvious choice for sphingolipid labeling, their 
use has only been reported by our group, likely because they are not commercially available.  
For comparison to metabolically labeled cells, lipidomics analysis of the sphingolipids 
was performed on unlabeled cell samples. The lipidomics analysis of the lipids extracted from 
unlabeled NIH3T3 mouse fibroblast cells showed that the majority of the sphingolipids, 
specifically about 60% of all sphingolipids in NIH3T3 mouse fibroblast cells, was C16-SM. This is 
consistent with the observation that C16-ceramide, the precursor of C16-SM, is a major ceramide 
species found in mammalian cells. Despite this, under normal conditions, the levels of CerS5 
and CerS6 are usually low in human tissues.17 Hence, we introduced pre-labeling step to prime 
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the cells so that they would be capable of processing high levels of sphingoid bases during the 
subsequent stable isotope labeling step. Because C16-SM was the major sphingolipid species 
found in the NIH3T3 mouse fibroblast cells and C16-ceramide is its precursor, our subsequent 
analyses focused on C16-SM and C16-ceramide. 
High mass resolution mass spectrometry (R=70,000) combined with HPLC allowed the 
detection of unlabeled and fully labeled (containing both 15N-sphingoid and 13C-fatty acid) C16-
SM with very little mass error. Although this high mass resolution is significant progress for lipid 
studies, two peaks within 0.00632 m/z, which is the difference between 13C and 15N, still could 
not be resolved. To address this issue, the two unresolved mass peaks were both assumed to 
have Gaussian profiles and to be superimposed on top of one another, resulting in a single 
unresolved peak located between their two m/z values. Though additional studies would be 
necessary to definitively verify this assumption, this approximation seems to be more accurate 
than the alternative approach in which terrestrial abundances of the rare isotope are used to 
estimate the contribution of each isotopologue to the unresolved mass peak. For example, after 
a short labeling time (30 min), the portion of 15N-sphingoid-labeled C16-SM was so low that 
subtraction of the portion of naturally occurring C16-SM with one 13C that was estimated from 
standard rare isotope abundances (0.422) gave negative incorporation of 15N, which is not 
possible. For longer labeling time, however, the incorporation that was calculated by assuming 
that the peaks from the two isotopologues were Gaussian and superimposed gave similar 
incorporation, within 5% difference, of the 15N incorporation that was calculated by subtracting 
the portion of C16-SM that naturally contained one 13C. The same principle was also applied to 
assess the label incorporation into other species. The peaks from 14N13C16 C16-SM (or ceramide) 
and 15N13C1512C1 C16-SM (or ceramide) were also assumed to be Gaussian and superimposed, 
although whether the cells can produce palmitate or palmitoyl CoA with only fifteen 13C from 
the13C-algal lipid mix is not known. Additional analysis of the 13C-algal lipid mix with LC-MS/MS 
would be necessary to assess whether the algal lipid mixture contained 12C113C15-palmitic acid. 
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It is also possible that another isobaric lipid eluted at the same retention time as C16-SM. These 
possibilities should be evaluated with consideration that different numbers of rare isotopes might 
be incorporated to the candidate lipids.  
The incorporation of 15N-sphingoids into C16-ceramide increased rapidly then slowly 
decreased while the incorporation into C16-SM increased continuously over labeling time. 
Similar patterns were shown in the literature with radioactive 3H-sphingoids,15  which is not 
surprising since these labeled sphingoid bases are chemically identical to the unlabeled species 
despite potential differences in the concentration of the labels and the cell types used in these 
studies. However, the unlabeled lipid species can be detected only when stable isotope labeling 
and mass spectrometry are employed. For the experiments described herein, about 60% of the 
C16-SM and 40% of the C16-ceramide would not have been detected if we had employed the 
same concentration of radioactive labels, assuming that it is possible, to label NIH3T3 mouse 
fibroblast cells and used thin film chromatography and autoradiography for detection. 
13C-fatty acid incorporation followed a trend that was fairly similar to 15N-sphingoid base 
incorporation. The most noticeable difference was observed for label incorporation into C16-
ceramide when longer labeling times were employed. While 15N incorporation into ceramide 
reached a maximum and then decreased, 13C incorporation instead reached a plateau and did 
not decrease. This could be due to the differences in the amount of each label that was 
available to the cells over time. The source of 13C-fatty acids used for labeling was a 13C-algal 
lipid mix that was complexed with defatted albumin. Algal lipids consist of triacylglycerols as well 
as free fatty acids.18 Therefore, the triacylglycerols would be able to further provide 13C-
palmitate for labeling through hydrolysis even if the free 13C-palmitate from the algal lipid mix is 
exhausted. On the other hand, the 15N-sphingoid bases would enter the cells through passive 
diffusion, as shown with a radioactive sphingosine,19 mix with the endogenous pool of sphingoid 
bases and be used for ceramide synthesis immediately. As a result, 15N-sphingoid bases would 
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be exhausted faster than 13C-palmitate for labeling sphingolipids. C16-ceramide with an 
unlabeled sphingoid can be generated by de novo synthesis from serine and palmitoyl CoA or 
the recycling pathway from the catabolism of unlabeled sphingolipids. Therefore, the decrease 
in 15N incorporation into C16-ceramide as the labeling time increases past 4 h likely coincides 
with an increase in the conversion of unlabeled sphingoid bases to C16-ceramide. The extent 
that the de novo sphingolipid biosynthetic pathway and the salvage pathway contributed to the 
generation of unlabeled ceramide is presently unknown. However, careful design of the labeling 
strategy would allow this aspect of sphingolipid metabolism to be addressed. 
The addition of 13C-fatty acids to the medium significantly lowered the ratio of both 15N-
labeled SM to ceramide and unlabeled (total) SM to ceramide. Given that one molecule of the 
sphingoid base and one molecule of palmitic acid is required to produce one molecule of 
ceramide, fatty acid addition may promote ceramide production by ensuring sufficient levels of 
the fatty acid starting material are available. Alternatively, some components in the 13C-algal 
lipid mix may downregulate SM synthesis or upregulate ceramide generation. Exogenous 
palmitate is reported to increase ceramide synthesis and decrease SM levels in C2C12 
myotubes, suggesting that palmitate may activate sphingomyelinases that convert SM to 
ceramide.20 The palmitate (or palmitic acid) or some other fatty acids in or produced from the 
lipid mixture may have the same effect in NIH3T3 mouse fibroblast cells. One other possibility is 
that the 13C-triacylglycerols, other neutral lipids in the 13C algal lipid mixture, or their metabolic 
products may compete with ceramide for a phosphocholine head group. SM is generated by 
transferring a phosphocholine head group from PC to ceramide, producing diacylglycerol 
(DAG). Because the 13C-triacylglycerols are catabolized to fatty acids that are incorporated into 
both glycerophospholipids as well as sphingolipids, the addition of the 13C-fatty acid mixture in 
parallel with the 15N-sphingoid bases may increase the need for phosphocholine in the cells. 
This competition for phosphocholine may slow down the conversion of ceramide to SM but 
further investigation would be necessary to confirm it. 
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In conclusion, this work demonstrates that stable isotope labeling in conjunction with LC-
MS analysis has great potential for sphingolipid metabolism studies, providing comprehensive 
information. The metabolic labeling of cells with 15N-sphingoid bases and 13C-fatty acids are 
useful tools to understand sphingolipid behavior. In contrast to traditional radiolabeling, this new 
method enables the measurement of unlabeled sphingolipid species as well as labeled 
sphingolipids. By combining multiple stable isotope labels and carefully designing the 
experimental conditions, new information about sphingolipid metabolism and behavior that could 
not previously been obtained is now within reach.  
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3.6 FIGURES AND TABLES 
 
 
 
 
Figure 3.1. Ten most abundant sphingolipids in unlabeled NIH3T3 murine fibroblast cells. 
Lipidomics analysis of the lipid extracts from these cells was performed as described in the 
Materials and Methods.  
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Figure 3.2. Incorporation of 15N-sphingoid bases into A: ceramide and B: sphingomyelin at 
various labeling times. NIH3T3 murine fibroblast cells were pre-labeled with 3 µM of 14N-
sphingoids for 3 days prior to labeling with 6 µM of 15N-sphingoid bases and 215 µM of 13C-fatty 
acids for the indicated times.  
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Figure 3.3. Incorporation of 13C-fatty acids in A: ceramide and B: sphingomyelin in murine 
mouse fibroblast cells after various labeling times. Data was acquired from the same cell 
samples as the data shown in Figure 3.2. 
 
  
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
0 5 10 15 20 25 
labeling time (h) 
13C incorporation in C16-ceramide 
avg. 
exp.1 
exp. 2 
exp. 3 
exp. 4 
exp. 5 
A) 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
0 5 10 15 20 25 
labeling time (h) 
13C incorporation in C16-SM 
avg. 
exp.1 
exp. 2 
exp. 3 
exp. 4 
exp. 5 
B) 
		53 
 
 
 
 
Figure 3.4 (cont.) 
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Figure 3.4 (cont.) 
 
 
Figure 3.4. Change in SM/ceramide ratios at various labeling times. A: the ratio of 15N-SM to 
15N-ceramide produced by metabolic incorporation of 15N-sphingoid bases. B: the ratio of 13C-
fatty acid-labeled SM and ceramide, C: the ratio of total (labeled and unlabeled) SM and 
ceramide.  
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Figure 3.5. Changes in A: 15N-sphingoid base incorporation and B: SM/ceramide ratio for 
metabolic labeling performs for 4 h and 24 h labeling with and without 13C-algal lipid mix. 
NIH3T3 mouse fibroblast cells were pre-labeled with 3 µM of 14N-sphingoid bases for 3 days 
prior to labeling with 6 µM 15N-sphingoid bases in the presence and absence of 215 µM of 13C-
algal lipids. 
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Table 3.1. List of the top 10 sphingolipids that were detected in NIH3T3 cellular lipids and their 
m/z values. 
 
Sphingolipids ions m/z value Chemical formula Relative abundance 
SM (d18:1/16:0) + H* 703.5749 C39H80O6N2P 100% 
GlcCer(d18:1/16:0) + H 700.5722 C40H78O8N 11% 
SM(d18:1/18:0) + H 731.6062 C41H84O6N2P 9% 
SM(d16:0/26:2) + H 813.6844 C47H94O6N2P 8% 
Cer(d18:1/16:0) + H 538.5194 C34H68O3N 5% 
SM(d18:1/16:1) + H 701.5592 C39H78O6N2P 4% 
Cer(d18:1/24:1) + H 648.6289 C42H82O3N 3% 
SM(d16:0/24:1) + H 787.6688 C45H92O6N2P 3% 
SM(d18:1/18:1) + H 729.5905 C41H82O6N2P 3% 
SM(d16:1/16:0) + H 675.5436 C37H76O6N2P 2% 
 
* It was first identified as SM (d18:0/16:1) by the database but manually identified as SM 
(d18:1/16:0) based on LC-MS/MS data.  
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Table 3.2. List of m/z values used to identify labeled and unlabeled ceramide and SM. 
 
 C16-ceramide C16-SM 
Isotope 
incorporation m/z 
Theoretical 
occurrance m/z 
Theoretical 
occurrance 
Naturally the 
most abundant 
(1) 
538.5199  703.5754  
One 13C 
contained, 
occurring 
naturally 
539.5233 0.368 of (1) 704.5788 0.422 of (1) 
15N labeled 539.5170  704.5724  
13C16 labeled 
(2) 554.5736  719.6291  
15N and 13C16 
labeled 555.5706 0.195 of (2) 720.6261 0.249 of (2) 
13C16 labeled both 
in acyl and 
backbone 
570.6273  735.6828  
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CHAPTER 4 
EVALUATING THE INVOLVEMENT OF ACID SPHINGOMYELINASE  
IN INFLUENZA VIRUS ENTRY* 
 
4.1 INTRODUCTION 
Changes in the local concentration of ceramide have been shown to play roles in 
curvature formation and membrane fusion in model systems1,2 and cells.3-6 For example, 
sphingomyelinase treatment was reported to induce the formation of inward vesicles that were 
not enriched with either clathrin or caveolin by pinching off from the plasma membrane, even 
when ATP was depleted.4 Sphingomyelinase treatment induced internalization of 10-30% of the 
plasma membrane in J774 macrophage cells and TRVb-1 cells (a variant of CHO cell). This 
clearly shows that local increases in ceramide levels influence trafficking by regulating 
membrane organization and fusion.  
As discussed in Chapter 1, ceramides can be produced through the de novo pathway or 
via degradation of sphingomyelin by sphingomyelinases (SMase). The SMase-dependent 
pathway is considered to be responsible for stress-induced ceramide generation.7 Mammalian 
SMases are classified as alkaline, neutral, or acidic in accordance with their optimal pH. So far, 
one alkaline SMase, four neutral SMases (nSMase1, nSMase2, nSMase3, and mitochondrial 
SMase) and one acidic SMase have been identified.8  
Alkaline SMase is almost exclusively found in intestinal mucosa and human liver.9 It was 
first found in 1969,10 but seems to have been forgotten based on the lack of papers on the 
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subject for about 20 years, although rapid progress was made on other SMases during this 
time. The lack of attention paid to alkaline SMase is likely because no genetic disorder is known 
to be caused by mutations in alkaline SMase. In addition, sphingolipid research has mainly 
focused on intracellular signaling and membrane organization, so extracellular enzymes such as 
alkaline SMase and secreted SMase (which will be discussed later) were largely neglected.11 
Nonetheless, recent studies show that alkaline SMase is responsible for the digestion of dietary 
sphingomyelins that are approximated to be about 300 mg per day.12 Knockout of this enzyme 
increased sphingomyelin and decreased ceramides in intestinal contents and induced mucosal 
hypertrophy.12 A recent report also showed that sphingolipids in the intestine, specifically S1P 
are involved in the occurrence of allergic diarrhea and pathogenic cell trafficking.13 
Sphingomyelin comprises a significant portion of the dietary sphingolipids,14 therefore alkaline 
SMase that cleaves sphingomyelin may affect the composition of acylated and unacylated 
sphingolipids in the intestinal lumen and intestinal tissues. Certainly more effort should be made 
to understand the roles and significance of alkaline SMase. 
Among the neutral SMases, nSMase2, also known as sphingomyelin phosphodiesterase 
3 (SMPD3), is thought to be the major SMase in cells that is responsible for ceramide signaling. 
Nonetheless, the first cloned nSMase was nSMase1, or sphingomyelin phosphodiesterase 2 
(SMPD2)15 which is ubiquitously expressed in almost all tissues and localized to the ER and 
Golgi.16 Although it hydrolyzes sphingomyelin in vitro, nSMase1 also hydrolyzes lyso-PC and 
lyso-PAF17,  and no sphingomyelin accumulation was observed in a mutant mouse line that was 
deficient in nSMase1.18 This and the discovery and cloning of nSMase2, which was first found in 
rat brain tissue,19 led to skepticism regarding whether nSMase1 is truly a sphingomyelinase. 
SMase2 is localized in the Golgi and plasma membrane, and it is predominantly considered to 
be the nSMase responsible for ceramide signaling in cells. Deletion of this gene impaired 
growth and development in mice, producing a dwarf mouse phenotype.20,21 Interestingly, the 
findings that mice lacking nSMase2 activity exhibit residual nSMase activity, and mutant mice 
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that were deficient in both SMPD2 and SMPD3 did not accumulate sphingomyelin18 argue 
against dismissing nSMase1 as a neutral sphingomyelinase. A third nSMase that has little 
homology to nSMase1 and nSMase2 was first identified in bovine brain22 and then in human 
tissues (mostly heart and skeletal muscles).23 A fourth neutral SMase, mitochondrial SMase, 
was fairly recently identified, first in zebrafish24 and then in mouse.25 Mitochondrial ceramides 
are reported to induce apoptosis,26,27 but additional research is required to fully elucidate its 
biological functions and significance. 
Acid SMase (aSMase) or sphingomyelin phosphodiesterase 1 (SMPD1) is the first 
SMase that was cloned in 1966.28 Its biological significance was elucidated soon after its cloning 
in  reports that Niemann-Pick disease patients were deficient in aSMase.29 A recessive mutation 
in the SMPD1 gene is the direct cause of two of the three types of Niemann-Pick disease 
(NPD), specifically type A and B.30,31 Type A NPD is characterized by rapid progressive 
neurodegeneration that leads to death by age 3 while type B NPD patients have much less 
severe symptoms and a longer life expectancy (up to adulthood).30 ASMase is a lipid catabolic 
enzyme that is localized in the lysosomes, and its role in lipid catabolism is supported by 
aberrant lysosomal lipid storage in NPD cells.32 Because of its subcellular localization, aSMase 
is also called lysosomal aSMase. Lysosomal aSMase is ubiquitously expressed in all tissues28 
and cell types33 and is thought to be involved in many stress-induced cell responses, including 
apoptosis,34 as well as in regulating membrane organization and endocytosis, as described in 
Chapter 1.  
The gene encoding for aSMase, SMPD1, expresses both lysosomal aSMase and 
another form of sphingomyelinase, secretory SMase (sSMase). Depending on the sorting 
pathway at the Golgi, the same pro-aSMase protein can be transported to the lysosomes 
(lysosomal aSMase) or secreted extracellularly (sSMase).35 These differences in trafficking 
pathways result in different glycosylation patterns on lysosomal aSMase and sSMase.31 
Although originating from the same gene, the enzymatic properties of these two SMases are 
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different. ASMase does not require Zn2+ and is active at low pH35. In contrast, sSMase requires 
Zn2+ and neutral pH for its enzymatic activity.35 Their turnover rates also differ, where the life 
time of lysosomal aSMase is less than 6 h, while sSMase is much more stable.36 Elevated 
sSMase activity has been detected in the serum of human patients with many diseases, such as 
type II diabetes, chronic heart failure, sepsis, and hypercytokinemia.36  
Because sphingolipids play critical parts in membrane (re)organization and 
internalization, as discussed above and in Chapter 1, it is not surprising that SMases have been 
implicated in infections by various pathogens ranging from bacteria, fungi, parasites, and 
viruses.37-39 In particular, host aSMase has been shown to control the entry of many pathogens, 
including Listeria monocytogenes,40 Neisseria meningitidis,41 Pseudomonas aeruginosa,42 
Mycobacterium avium,40 Trypanosoma cruzi,43 choriomeningitis virus,40 Ebola virus,44 and 
measles virus.45 Here we investigated how SMPD1 levels in host MDCK cells affect influenza 
virus entry using RNAi. We found that influenza virus entry was only slightly affected by the 
reduced aSMase levels. However, the influenza virus seemed to upregulate the levels of mRNA 
for SMPD1 and other sphingomyelinases. These results suggest that SMPD1 may play an 
important role in influenza virus infection.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Lipofectamine RNAiMAX, EDTA-free Halt Protease and Phosphatase Inhibitor Cocktail 
100X were purchased from Thermo Fisher. Mission siRNA Universal Negative Control #1 and 
desipramine hydrochloride were purchased from Sigma-Aldrich. Polyclonal rabbit primary 
antibody against SMPD1 protein (ARP35630_P050) of many species including dog was 
purchased from Aviva Systems Biology. Goat polyclonal primary antibody against β-actin 
(ab8229) and rabbit polyclonal antibody against influenza A virus nucleoprotein (ab22285) were 
purchased from Abcam. HRP-conjugated anti-rabbit secondary antibodies from Cell Signaling 
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Technology (#7074) and Thermo Fisher (A16104) were used. Goat secondary antibody against 
rabbit antibody with Alexa Fluor 488 conjugate (A11008) was purchased from Invitrogen. 2X 
Laemmli sample buffer, the Clarity Western ECL blotting substrate that was used for 
chemiluminescence, iTaq Universal One-Step RT-qPCR kit (1725150), and 4-20% 
polyacrylamide Mini-PROTEAN precast gels were from Bio-Rad. Glass bottomed petri dishes 
were obtained from CellVis. Paraformaldehyde was purchased from Electron Microscopy 
Sciences. Alexa488 goat anti-rabbit IgG Hoechst 33342 nuclear stain, and Lipofectamine 
RNAiMAX were purchased from Life Technologies. RNeasy mini kit for RNA isolation and 
Cf_SMPD1_2_SG QuantiTect Primer Assay (QT01646463, targeting XM_542452, XM_857542) 
were from Qiagen. Primers for canine GAPDH and influenza virus M1 protein were purchased 
from IDT. Fresh chicken blood was obtained from the Department of Animal Sciences at the 
University of Illinois Urbana-Champaign. V-bottom 96 well plates were purchased from Sarstedt. 
MDCK cells (ATCC® CCL-34™) and the A/Aichi/2/68 (H3N2) strain of the influenza virus 
(ATCC® VR-1680™) were purchased from ATCC. 
4.2.2 Cell culture and influenza virus propagation 
MDCK cells (ATCC® CCL-34™) were grown in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin in a 5% CO2 incubator at 
37°C. MDCK cells were grown in 12 well plates for Western blots, 24 well plates for RT-qPCR, 
and glass bottomed dishes for confocal microscopy. The A/Aichi/2/68 (H3N2) strain of the 
influenza virus was  propagated as described previously.46 Virus stock solutions were prepared 
in DMEM with 7.5% BSA, 25 mM HEPES and 2 μg/mL trypsin, and quantified by 50% tissue 
culture infectious dose assay (TCID50) and hemagglutination assay46 and calculated by the 
method of Reed and Muench.47  
4.2.3 RNA interference and desipramine treatment 
RNA interference with siRNAs was used to manipulate SMPD1 levels in MDCK cells. 
The siRNAs against canine SMPD1 (XM_542452.4) were designed and manufactured by 
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Sigma-Aldrich. The sequences of the siRNAs are GUCUCAUCUCUCUCAAUAUdTdT (sense), 
AUAUUGAGAGAGAUGAGACdTdT (antisense), GAGGAUAGCUGUGGUAAGAdTdT (sense), 
UCUUACCACAGCUAUCCUCdTdT (antisense), GAGACAAGGUACAUAUAAUdTdT (sense), 
AUUAUAUGUACCUUGUCUCdTdT (antisense). Mission siRNA Universal Negative Control #1 
(Sigma-Aldrich) was used as a negative control. For transfection, MDCK cells were seeded in 
either 12 well plates or 24 well plates. One day after seeding, the cells were transfected with the 
siRNAs complexed with Lipofectamine RNAiMAX. After incubation with the transfection complex 
for 6 h, the cells were incubated in fresh media without transfection complex until either 
influenza virus infection or an assay was performed. Desipramine stock solution (25 mM) was 
prepared in water and stored at -20°C.  
4.2.4 Influenza virus infection 
After washing with PBS two times, the cells were incubated with virus stock solution 
diluted in DMEM (final concentrations of BSA and trypsin in the culture medium were 0.2% and 
2 µg/mL, respectively) at a multiplicity of infection (MOI) of ~10 (determined by TCID50 per 
number of cells) for 30 min 4°C, and then at 37°C for 30 min. Then the cells were washed with 
the virus media (DMEM with 0.2% BSA and 2 µg/mL trypsin) to remove unbound virus, placed 
into fresh virus media, and incubated at 37°C for the specified time. 
4.2.5 Western blot 
The medium in the cell culture was aliquoted for Western blot analysis. Then the 
transfected cells were removed from the culture medium, thoroughly washed with PBS, lysed 
with lysis buffer containing 1% Triton X-100, 20 mM Tris-HCl, 137 mM NaCl, 10% glycerol, 2 
mM EDTA supplemented with EDTA-free Halt Protease and Phosphatase Inhibitor Cocktail 
following the manufacturer’s protocol. The cell lysates and the aliquoted media were mixed with 
Laemmli sample buffer containing mercaptoethanol (5% v/v in final concentration) and heated at 
85°C for 5-10 min. The proteins in the cell lysates and the media were separated by 
electrophoresis on 4-20% polyacrylamide Mini-PROTEAN precast gels using a Mini-Protean 
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system. The proteins in the gels were transferred to either a PVDF or nitrocellulose membrane, 
and blocked for 30 min with 2.5% skim milk powder in Tris-buffered saline and Tween 20 (TBST) 
buffer at room temperature. The membranes were incubated in SMPD1 primary antibody 
(1:1000) or β-actin primary antibody (1:500) diluted in TBST with 1% skim milk powder overnight 
at 4°C. After washing three times, the membranes were incubated with HRP-conjugated 
secondary antibody diluted in TBST with 1% skim milk powder following the manufacture’s 
protocols for 1 h at room temperature and visualized by chemiluminescence using Clarity 
Western blot ECL and ImageQuant LAS 4010 imager.   
4.2.6 Immunofluorescence and confocal fluorescence microscopy 
The cells were fixed with 1% paraformaldehyde in PBS at room temperature and 
permeabilized with 0.1% Triton-X in PBS for 10 min on ice. After thorough washing with PBS, 
the cells were blocked with 1% BSA in PBS for 30 min at room temperature, incubated with the 
diluted rabbit primary antibody against influenza A virus nucleoprotein in PBS with 1% BSA for 1 
h at room temperature and then washed with 1% BSA in PBS at room temperature three times. 
The cells were incubated with the anti-rabbit secondary antibody conjugated with Alexa 488 
diluted in PBS with 1% BSA for 1 h at room temperature and washed with 1% BSA in PBS three 
times. Hoechst 33342 was added and incubated for 10 min for nuclear staining following 
manufacturer’s protocol. The samples then were imaged using a Carl Zeiss LSM 700 at room 
temperature. A 488 nm laser and a 405 nm laser were used to excite Alexa 488 fluorophore and 
Hoechst 33342 respectively.  
4.2.7 Quantitative reverse transcription polymer chain reaction (RT-qPCR) 
RNA in the cells and the media were extracted using RNeasy mini RNA isolation kit from 
Qiagen following the manufacture’s protocol. The concentration of RNA in the final product was 
measured using NanoDrop. A commercially available primer assay for canine SMPD1 was 
used. The primer sequences used for influenza M1 gene were based on literature reports48-50 
where the exact sequences are 5’-AGATGAGTCTTCTAACCGAGGTCG-3’ and 5’-
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TGCAAAAACATCTTCAAGTCTCTG-3’. The primer sequences for dog GAPDH were 5’-
AACATCATCCCTGCTTCCAC-3’, 5’-GACCACCTGGTCCTCAGTGT-3’. Reverse transcription 
and amplification were performed using the primers and iTaq Universal One-Step RT-qPCR kit 
following the manufacturer’s protocol using a ABI 7900 real time PCR machine.  
 
4.3 RESULTS 
4.3.1 Expression levels of aSMase in SMPD1 knockdown MDCK cells and media 
First, the SMPD1 gene expression levels in the MDCK cells treated with SMPD1 
targeting siRNAs or control siRNA were evaluated by RT-qPCR at 48 h posttransfection. The 
SMPD1 gene expression level decreased by at least 50% in SMPD1 targeting siRNA treated 
cells compared to control siRNA treated cells in two biological replicates (Figure 4.1A). Next, the 
SMPD1 protein levels (which include aSMase and sSMase) in the MDCK cells and the media 
after RNAi were evaluated by Western blot at 48 h posttransfection. Even though aSMase is 
considered to be a lysosomal housekeeping protein,31 the level of cellular SMPD1 detected by 
Western blot was very low in all samples to a similar degree, even in the sample without siRNA 
treatment (Figure 4.1B). Because aSMase can be secreted through lysosomal exocytosis51,52 
and sSMase is expressed from the encoding SMPD1 gene, the level of extracellular SMPD1 
protein was also assessed by collecting the media and subjecting it to Western blot. Very 
intense bands were detected in the blot of all media samples, indicating the presence of 
aSMase or sSMase in the media. The media that was collected from the siRNA-treated cell 
culture showed only slightly weaker signals than the media from the cells treated with control 
siRNA. However, these results did not necessarily indicate that the knockdown was ineffective 
because further investigation revealed that the FBS that had been added to the culture medium 
contained a high level of sSMase53 and the antibody used in this study detects bovine SMPD1 
protein as well as canine SMPD1 protein. Therefore, when the 6 h of transfection procedure 
was complete, the cells were incubated in serum-free media supplemented with BSA at final 
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concentration of 0.2% for 42 h, and then the cell lysates and culture media were collected and 
analyzed by Western blot. Figure 4.1B shows again that the bands from cellular SMPD1 were 
much weaker than those from extracellular SMPD1, as observed when FBS was added to the 
media. However, it also shows that knockdown with siRNAs lowered the levels of cellular 
SMPD1 by approximately 50% (Figure 4.1C). Although the Western blot showed that the media 
from all the cells contained extracellular SMPD1, the band for the cells transfected with SMPD1 
siRNA was weaker than that of the control and untransfected MDCK cells, indicating some 
knockdown of SMPD1. However, the knockdown of extracellular SMPD1 is difficult to quantify 
using the blot shown in Figure 4.1C because the extracellular SMPD1 would have accumulated 
in the medium before the expression of this proteins started to decrease. Nevertheless, these 
results show that SMPD1 knockdown using siRNAs reduced the levels of both cellular and 
extracellular SMPD1.  
4.3.2 Visualization of influenza virus entry in SMPD1 knockdown and control MDCK cells 
by immunofluorescence  
Next, immunofluorescence microscopy was used to investigate how lowering SMPD1 
levels with RNAi and desipramine, a pharmacological inhibitor of lysosomal aSMase, affects 
influenza virus entry. The MDCK cells were transfected with either SMPD1 siRNAs or control 
RNAs for 6 h, and then the media were substituted to either 10% FBS or 0.2% BSA in DMEM 
without transfection complex. At 48 h post-transfection, the MDCK cells that were transfected 
with SMPD1 siRNAs or negative control RNAs were infected with 10 MOI of the influenza virus. 
At 1.5 h post infection (hpi), the cells were fixed, permeabilized, immunolabeled for influenza 
virus nucleoprotein, and imaged with confocal fluorescence microscopy. The nucleoprotein was 
imaged because it locates to the nucleus shortly after the influenza virus enters the cell. Figure 
4.2 shows the confocal fluorescence microscopy images of the nucleoproteins in MDCK cells 
with and without SMPD1 knockdown. Little difference was observed in the fluorescence levels 
within the SMPD1 knockdown cells and control siRNA-treated cells that were incubated in 
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medium containing 10% FBS after transfection but before influenza infection (Figure 4.2A). 
When the cells were incubated in DMEM that contained 0.2% BSA instead of 10% FBS for the 
48 h after transfection but before infection, SMPD1 knockdown appeared to slightly decrease 
the amount of nucleoproteins in the cell and also its localization at the nuclei (Figure 4.2B) upon 
infection.   
4.3.3 Quantification of influenza virus entry in SMPD1 knockdown and control MDCK 
cells by RT-PCR  
Next, we assessed the virus entry in SMPD1 knockdown, and control MDCK cells that 
were transfected with control siRNA by measuring the influenza virus M1 gene level using RT-
qPCR. The MDCK cells were transfected and infected in the same way as described above. In 
addition, RT-qPCR was also used to measure M1 expression in influenza-infected MDCK cells 
in which aSMase activity was pharmacologically reduced by incubating the cells in the presence 
of desipramine (25 µM) overnight prior to the infection. The total RNA of the infected cells was 
collected at 1.5 hpi. The relative amount of internalized virus was quantified by measuring the 
level of the virus M1 RNA and comparing it to the level of cellular GAPDH, which is a 
housekeeping gene. As shown in Figure 4.3A, the virus M1 gene level in the infected MDCK 
cells subjected to SMPD1 knockdown was about 80% of that of the infected MDCK cells that 
were subjected control siRNA transfection (infected control cells), indicating SMPD1 knockdown 
slightly decreased the infection (single measurement). A similar decrease in the virus M1 gene 
level was measured in the desipramine-treated cells after infection.  
The SMPD1 levels in the infected cells were also measured (Figure. 4.3A, red). Without 
infection, knockdown with the siRNAs decreased the SMPD1 level to no more than 50% of that 
measured in the cells treated with control siRNA (Figure 4.1A). However, the SMPD1 level 
measured in the SMPD1 knockdown cells after infection was about 60% of the SMPD1 mRNA 
level measured in the infected control cells after infection. This reduced level of SMPD1 
knockdown in the presence of infection may suggest that the influenza virus itself upregulates 
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SMPD1 levels. As shown in Figure 4.3B, at 1.5 hpi, SMPD1 knockdown did not produce a 
statistically significant reduction in M1 levels when serum free media was used after the 
transfection and before the infection, which is inconsistent with the confocal microscopy data 
presented above. In fact, very high variations in M1 and SMPD1 levels were observed in the 
three replicate measurements. This high variance in the three repeats may be due to small 
variations in MOI, the time after transfection at which infection began, or the time after that 
infection was allowed to proceed.  
We also measured the M1 level at 8 hpi, which is approximately the duration of one 
infection cycle (Figure 4.3C). The M1 levels barely decreased, by only about 10%, in the 
SMPD1 knockdown cells. In addition, the level of SMPD1 in these knockdown cells was about 
75% of that in control cells, which indicates the SMPD1 level further increased in the presence 
of influenza virus infection. However, desipramine treatment significantly lowered M1 
expression, down to about 30% of control siRNA-treated cells, in influenza-infected cells 8 hpi, 
but increased SMPD1 levels to ~250% of that measured in control siRNA-treated cells.  
4.3.4 Change of SMPD1 level by influenza virus infection 
Our data above suggest that influenza virus infection was correlated with changes in the 
level of SMPD1 mRNA. To confirm this, the level of SMPD1 mRNA in influenza virus infected 
cells that were not treated with any siRNA was compared to that in cells that were not infected 
with virus (mock infected) by measuring SMPD1 mRNA levels using RT-qPCR. At 2 hpi, the 
SMPD1 levels in the virus-infected cell samples were consistently higher (about 40%, 2 
replicates) than that of the mock-infected control cells (Figure 4.4). Although the relative SMPD1 
levels measured in the two influenza virus-infected replicates were highly variable at a time of 4 
hpi, they seemed to return to that found in uninfected cells by 6 hpi. These findings confirm that 
SMPD1 mRNA increases during the early stages of influenza virus infection. This suggests that 
sphingolipids, and particularly those generated by SMPD1, are involved in the early stages of 
influenza virus replication.  
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4.4 DISCUSSION 
Pathogen infection requires significant rearrangement of the host and viral membranes, 
therefore it is not surprising that host membrane lipids can influence virus infection and 
replication.54 Several studies show that aSMase is important in the entry of not only viruses but 
also other pathogens including bacteria, fungi, and parasites, into the cytosol and their 
subsequent escape.40-45 These studies suggest that ceramide-enriched domains induced by 
SMase are essential for pathogen entry. For example, non-enveloped viruses that are known to 
pierce or rupture the membrane, such as adenovirus, were recently reported to hijack the host 
cell’s membrane repair mechanisms to facilitate entry.55 A key event in membrane repair 
process is to enhance the endocytosis of damaged membranes by the secretion of aSMase 
through lysosomal exocytosis in response to Ca2+ influx at the sites of membrane damage. The 
adenovirus promotes its entry by inducing secretion of lysosomal aSMase and triggering 
ceramide-enriched domain formation. Although the entry of enveloped viruses is very different 
from that of non-enveloped viruses, it is also significantly affected by aSMase. Ebola virus 
particles were reported to strongly associate with sphingomyelin-rich regions in the plasma 
membrane and surface-localized aSMase.44 Pharmacological inhibitors and RNAi inhibited the 
infection of Ebola virus and Ebola virus pseudotyped virus in HeLa cells. Therefore, we 
hypothesized that aSMase would regulate influenza virus infection, and focused on the role of 
aSMase in the early phase of influenza virus infection.  
Here we used MDCK cells as the host for influenza infection because they were used to 
propagate our influenza virus strain, and this cell line is commonly used for basic influenza 
research and vaccine production.56-59 Prior to infection, cellular SMPD1 protein was barely 
detectable in the MDCK cells, which was somewhat unexpected because aSMase is thought to 
be a housekeeping protein in the lysosomes.31 A lack of antibody recognition is unlikely 
responsible for the discrepancy between our expectations and the experimental results 
because, interestingly, using the same antibody, our Western blot data show that a significant 
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amount of SMPD1 was secreted from the MDCK cells into the medium. Whether the protein 
detected by the SMPD1 antibody in the media was aSMase, sSMase, or a mixture of the two is 
not known. In human cells, sSMase undergoes no proteolytic processing from pro-SMase and 
has a reported molecular weight of 75-80 kDa, while aSMase is produced by more extensive 
cleavage of pro-aSMase at the lysosomes where its molecular weight decreases to 65 kDa, and 
eventually down to a 52 kDa protein that is mostly inactive.60 Not much information is available 
on canine SMPD1 proteins. The molecular weight of dog SMPD1 protein is calculated to be 69 
kDa based on the canine genome.61 This is slightly higher than the molecular weight we 
observed in the Western blot (approximately 63-65 kDa). Post-translational modification of 
SMPD1 proteins in canine cells has not been studied. However, considering that the molecular 
weight of extracellular SMPD1 detected on our blot was smaller than that of cellular SMPD1, the 
extracellular SMDP1 that we detected may have been the hydrolyzed form of aSMase that was 
secreted through lysosomal exocytosis. Indeed, lysosomal exocytosis occurs not only in 
specialized secretory cells (such as neurons), but also in both polarized and nonpolarized cells, 
where it is Ca2+-dependent.62 Whether the extracellular SMPD1 is active, and if so, what 
conditions (pH and Zn2+ concentration) optimize its activity would need to be determined to 
establish the identity of the extracellular SMPD1.  
Visualization of influenza nucleoproteins by immunofluorescence 1.5 h after infecting 
cells that had been transfected with SMPD1 siRNAs and control siRNAs prior to the infection 
suggested that exposing the cells to serum after transfection influenced whether SMPD1 
knockdown affected virus entry. This is consistent with our observation that the knockdown was 
more effective in terms of protein level when the cells were incubated in serum-free medium 
following transfection (Figure 4.1). Noteworthy, influenza infection was always performed under 
serum-free conditions. The cells that were incubated in serum-free medium prior to infection 
may have acclimated to this medium condition, while the cells that were incubated in 10% FBS, 
the normal cell growth media for MDCK cells, would have been adjusting to the new culture 
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environment during virus infection. It is not clear how this need to acclimate during virus 
infection might affect virus entry, but this factor should be considered when designing future 
experiments, since serum deprivation not only alters protein synthesis capacity63 and secretion64 
but also induces global change in cell signaling responses.65  
To measure the extent of the virus inside the cells, we measured the M1 RNA level that 
would be proportional to the extent of the infection by RT-qPCR. RT-qPCR is advantageous 
over traditional assays for investigating the early stage of infection because it is much more 
sensitive than the traditional assays by principle. Our data showed that at 1.5 hpi, the effect of 
SMPD1 knockdown on influenza virus infection was not statistically significant. Slightly lower M1 
RNA levels were observed in SMPD1 knockdown cells incubated in serum-containing medium 
prior to infection (Figure 4.3A), but the reproducibility of these results was not assessed, and our 
immunofluorescence results (Figure 4.2A) showed no difference in M1 levels, thus viral entry 
under these conditions. The data from the three biological replicates of the cells incubated in the 
serum free medium after siRNA treatment and before infection (Figure 4.3B) show high 
variation, demonstrating that SMPD1 knockdown has no statistically significant effect on 
influenza virus entry. These results are contrary to the previous reports on the effect of aSMase 
in other pathogenic infections. The knockdown here may not have been sufficient to induce 
significant, reproducible changes in influenza virus entry. Moreover, the cellular level of SMPD1 
protein in this specific cell line (MDCK) may be too low to observe an effect of SMPD1 
knockdown. Figure 4.1 shows that, unexpectedly, the cellular SMPD1 protein level in the 
uninfected MDCK cells was very low even without knockdown, and the amount of extracellular 
SMPD1 protein secreted into the medium over the 1.5 h duration of influenza infection may not 
have been sufficient to affect influenza virus entry. The effects of SMPD1 on influenza virus 
infection might become more clear if cells that endogenously express higher levels SMPD1 or 
were manipulated to overexpress SMPD1 were employed. Alternatively, SMPD1 proteins may 
not influence the early stages of influenza infection. Interestingly, SMPD1 gene expression 
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levels in the SMPD1 knockdown cells compared to control siRNA treated cells was higher in the 
infected cells than uninfected cells (Figure 4.1A vs. Figure 4.3), suggesting that the virus 
internalization may induce an increase in cellular SMPD1 expression. This possibility was 
assessed with the subsequent experiments and will be discussed below.  
Interestingly, while the difference in virus M1 RNA levels were not statistically significant 
(Figure 4.3B), the virus nucleoprotein levels detected by immunofluorescence showed a slight 
decrease in SMPD1 knockdown cells compared to control siRNA treated cells (Figure 4.2B) in 
the infected cells that were incubated in the serum free media between the transfection with 
siRNAs and the infection with influenza virus. Among the three biological replicates in the RT-
qPCR data in Figure 4.3B, only one SMPD1 knockdown cell sample had a slightly lower virus 
M1 level than control siRNA treated cells. The possibility of nonspecific binding in 
immunofluorescence or irreproducible knockdown prior to the infection cannot be excluded and 
needs to be tested under similar experimental conditions. However, it should be also noted that 
the levels of virus RNA (as well as virus mRNAs) change in the course of infection, even at 1.5 
hpi.66 Interestingly, a report66 showed that upon influenza virus infection, the virus M1 RNA level 
first decreased until 2 hpi and then increased until 6 hpi. Based on that, the increased virus M1 
RNA level in SMPD1 knockdown cells compared to control siRNA treated cells may indicate the 
delay in the decrease of virus M1 RNA by SMPD1 knockdown, which would, then, be not 
contrary to the immunofluorescence data. However, more experimental evidence is required to 
confirm whether the same change in virus M1 RNA also occurs during infection with the virus 
strain used in this study, and whether and how SMPD1 knockdown affects these changes in M1 
RNA.  
Virus infection alters host proteins and genes. Some enveloped viruses, such as Sindbis 
virus (the prototypic alphavirus)67 and measles virus45 as well as the non-enveloped rhinovirus68 
increased the host aSMase activity upon infection. Therefore, it is also plausible that influenza 
virus infection may alter host gene expression, either directly by viral components, or indirectly 
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as a cell response to infection. Our RT-qPCR data indicate that SMPD1 levels increased during 
the early stages of influenza virus infection. The proteins whose levels were altered during 
influenza virus infection (H1N1) in MDCK cells were previously documented with mass 
spectrometry-based quantitative proteomics using the approach of stable isotope labeling by 
amino acids (SILAC) in cell culture.69 Although changes in SMPD1 were not reported, this may 
be due to the low level of cellular SMPD1 proteins in MDCK cells, as shown in our data. The 
increased SMPD1 levels we observed at the early stage of influenza infection is in line with the 
observation that the levels of proteins that are related to metabolic processes, including lipid 
metabolism, were increased at the early phase (4 hpi) of infection.69 Interestingly, this study 
revealed that acid ceramidase 1(ASAH1), which cleaves ceramides to sphingosine and fatty 
acids, was among the proteins that were increased at the early phase of the infection, implying 
the significance of sphingolipids during the early phase of the infection. In addition to eliciting 
endocytosis, ceramides can induce cytoskeletal reorganization and apoptosis, as discussed in 
Chapter 1, which coincides with the typical morphological changes that the host cells undergo 
during influenza virus infection. But our data, together with the aforementioned report,69 
demonstrate that influenza virus influences host sphingolipid metabolism. It also renders 
another possible scenario in our observation that inhibiting SMPD1 using siRNA only slightly 
lowered the infection. Many reports used lower MOI than were used herein, typically below 0.5 
MOI. This lower MOI would make it more challenging to detect the virus at the early phase of 
the infection and synchronize the infection, but reduces the cytopathic effect of the virus. In our 
experiments, some virus particles may have been internalized after the SMPD1 levels became 
elevated due to virus infection, which could make it difficult to ascertain the effects of lowering 
SMPD1 on virus entry.   
Interestingly, desipramine treatment lowered the M1 gene levels 8 hpi by about 65%, 
whereas treatment with siRNAs had a minimal effect, reducing M1 expression by about 10%. 
The decrease in M1 levels observed after desipramine treatment may not be due to lower 
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aSMase protein levels. Though desipramine and other cationic amphiphilic drugs such as 
chlorpromazine and chloroquine are frequently used as aSMase inhibitors, these drugs have 
more effects than just inhibition of aSMase. Desipramine is also a potent inhibitor of acid 
ceramidase,70 a catabolic enzyme that degrades ceramide to sphingosine in lysosomes as 
mentioned above. Little is currently known about the roles of acid ceramidase in infection, but 
considering the broad effects of phosphorylated sphingosine (S1P) in cells, acid ceramidase 
that produces sphingosine may have important roles in infection. More importantly, these 
cationic amphiphilic drugs raise the pH of the lysosomes 71 and late endosomes.72,73 This is an 
important side effect because the low pH in late endosomes elicits changes in the influenza 
envelope protein, hemagglutinin, that are required for release of the virus ribonucleoprotein 
complex into the cytosol during virus entry.74 The increase in late endosomal pH induced by 
desipramine would inhibit the escape of the influenza virus from the endolysosomes75 and 
prevent the replication of virus genes. Therefore, the inhibitory effect of desipramine on 
influenza infection cannot be attributed to aSMase inhibition.  
It has been previously reported that the de novo synthesis of sphingolipids and 
sphingomyelin synthase 1 (SGMS1) are essential for the transport of influenza virus proteins.76 
Our data suggest the possibility that sphingolipids are involved in the early phase of the 
infection, which including entry and escape from the endosomes. However, further infection 
experiments that involve use of a pharmacological inhibitor that is specific to aSMase(and 
inactive against acid ceramidases such as siramesine,77 and complete knockout of SMPD1 
gene expression are required to verify these findings and better elucidate the involvement of 
SMPD1 in influenza virus infection.  
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Figure 4.1 (cont.) 
 
 
Figure 4.1. Detection of SMPD1 gene expression level (A) and SMPD1 proteins in MDCK cells 
and their conditioned culture media (B, C) after RNAi. A: MDCK cells were transfected with 
siRNAs against SMPD1, and negative control RNAs for 6 h. The cells were transferred to fresh 
media consisting of DMEM with 10% FBS. After 42 h, cellular RNAs were extracted from the 
cells and subjected to RT-qPCR. The SMPD1 mRNA levels relative to GAPDH (housekeeping) 
mRNA level of SMPD1 siRNA treated cells were compared to those of control siRNA treated 
cells. B: MDCK cells were transfected with siRNAs against SMPD1, and negative control RNAs 
for 6 h. The cells were transferred to fresh media consisting of DMEM with 10% FBS twice, 
once right after the transfection and again 24 h prior to sample collection. For comparison, cells 
that were not transfected with siRNA were cultured in the same media for the same time 
intervals prior to sample collection. 10 µl aliquots of the media that had been conditioned for 24 
h were also collected from the transfected and non-transfected cells and subjected to Western 
blot. C: MDCK cells were transfected the same as A. The media were substituted to DMEM with 
0.2% BSA once after the transfection. Cells that were not transfected with siRNA were also 
cultured under the same conditions. 20 µL aliquots of media that had been conditioned for 42 h 
were collected for Western blot.  SMPD1: cells subjected to siRNA knockdown of SMPD1; 
CTRL: cells transfected with control siRNA; (-) MDCK cells that were not transfected. 
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Figure 4.2. Confocal fluorescence microscopy images of nuclear proteins in infected cells with 
and without knockdown of SMPD1. The z-projection images were produced by combining the z-
stack images collected with 0.25 µm interval between two adjacent stacks. A: MDCK cells were 
transfected with siRNAs against SMPD1, negative control RNAs for 6 h, and then the cells were 
incubated in fresh siRNA-free media consisting of DMEM with 10% FBS for 48 h after the 
transfection. At 48 h post-transfection, the cells were infected with influenza virus at ~10 MOI. At 
1.5 hpi the cells were fixed, permeabilized and immunolabeled against influenza A 
nucleoprotein. B: MDCK cells were transfected the same as A, where the media were changed 
to DMEM with 0.2% BSA after the transfection. Infection, fixation, permeabilization and 
immunolabeling were performed the same as in A.  
A) 
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Figure 4.3. The relative levels of M1 and SMPD1 in the infected MDCK cells after knockdown of 
SMPD1 or desipramine treatment. A: Fold change in virus M1 RNA and SMPD1 mRNA levels 
measured in SMPD1 knockdown cells and desipramine-treated cells relative to GAPDH (the 
housekeeping gene) compared to control siRNA treated cells at 1.5 hpi. The cells were 
transfected, incubated in 10% FBS, and then infected as described in Figure 4.2A. For 
desipramine treatment, the cells were treated with 25 µM of Desipramine overnight prior to the 
infection. B. Fold change in virus M1 RNA and SMPD1 level of three repeats of SMPD1 
knockdown cells relative to GAPDH compared to control siRNA treated cells at 1.5 hpi. The 
cells were transfected, incubated in 0.2% FBS, and then infected as described above. C: Fold 
change in M1 and SMPD1 at 8 hpi. The cells were treated in the same as A.  
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Figure 4.4. SMPD1 expression levels change with time post-influenza infection. MDCK cells 
were infected with influenza virus at ~10 MOI. The total RNAs were collected at the indicated 
post-infection time and the levels of SMPD1 mRNA were measured by RT-qPCR.  
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CHAPTER 5 
MANIPULATING PROTEIN CORONA COMPOSITION BY PRE-COATING THE 
NANOPARTICLES WITH PROTEINS AND ITS IMPACT ON CELLULAR UPTAKE* 
 
5.1 INTRODUCTION 
Conventional drug administration would benefit from implementing efficient drug delivery 
systems. Improving drug delivery systems so that they efficiently target the drug to the diseased 
tissue, and not healthy cells, is expected to lower the required drug dose and reduce possible 
side effects. To achieve these, smart delivery systems have been designed from various 
materials and implemented in order to enhance target specificity, circulation time, and drug 
release profiles.1-4  
Nanotechnology has been heavily exploited for these novel delivery systems. 
Nanoparticle-based targeted drug delivery offers multiple advantages over conventional drug 
																																																						
*	 This chapter presents portions of work which appeared in and has been reprinted with 
permission from:  
Biomaterials. Mirshafiee, V., Kim, R., Park, S., Mahmoudi, M. & Kraft, M. L. "Impact of protein 
pre-coating on the protein corona composition and nanoparticle cellular uptake", Biomaterials 
75, 295-304 (2016). 
The publication in Biomaterials was coauthored by Raehyun Kim, Vahid Mirshafiee, Soyun 
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characterized the nanoparticles, and performed LC-MS/MS analysis and flow cytometry. R.K. 
performed protein separation, prepared cell samples for flow cytometry and microscopy, 
performed microscopy, immunodot blot and analyzed the data. S.P. prepared samples for 
microscopy and performed immunodot blot with RK's assistance. MM planned experiments and 
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administration. The small sizes of the nanoparticles allow extravasation through blood vessels 
and tissues.5 This is especially advantageous for targeting solid tumors because tumor 
vasculature is much more permeable than normal vasculature due to its defective structure,2,6 
which is known as the enhanced permeability and retention (EPR) effect.7 By designing nano-
sized drug delivery systems that penetrate tumor blood vessels, but not normal ones, which is 
called passive targeting, it would be possible to selectively target solid tumors. Another 
advantage of using nanoparticle systems for drug delivery is that the surfaces of the 
nanoparticles can be easily functionalized and modified for more specific targeting,5 which is 
also called active targeting. Recently, active targeting has been heavily explored as information 
on the surface receptors or epitopes overexpressed in cancer cells has become available.2 
Various ligands (folate8 and transferrin9,10), antibodies (anti-HER211 and anti-CD1912) and 
peptides (RDG peptide13,14) have been exploited for targeting surface proteins that are known to 
be overexpressed in cancer cells. However, most active targeting strategies have not been 
successful in vivo, in part because the plasma proteins that adsorb on the nanoparticles, namely 
the protein corona, affects uptake efficiency,15 drug release profiles16 and biodistritution.17,18,19 
Polyethylene glycol (PEG) has been grafted to the nanoparticles to lower this protein binding 
and increase circulation time, but this doesn’t completely inhibit the adsorption of plasma 
proteins.20 
A possible alternative strategy is to utilize the proteins in the blood that form the protein 
corona, instead of removing them, for targeting. The surface of the nanoparticle can be 
manipulated for enriching the protein corona with certain desired proteins. For instance, a 
polysorbate-80 pre-coating on the nanoparticles enriched the protein corona with apolipoprotein 
B and E, which could enhance the transport of the nanoparticle across the brain blood barrier.21  
Here we examined whether manipulating the protein corona composition is feasible and 
useful for active targeting. Specifically, we assessed whether enriching certain plasma proteins 
in the protein corona can enhance targeting efficiency and uptake by select cells. Although 
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undesired in most targeted anticancer drug delivery applications, opsonin-triggered endocytosis 
in immune cells was utilized as a model system to evaluate targeting efficiency of the 
nanoparticles and to test the feasibility of our approach, because it is very well established and 
it may be useful for treating autoimmune diseases or diseases of immune cells. Silica 
nanoparticles were pre-coated with γ-globulins to enrich the protein corona with opsonins when 
the nanoparticles were exposed to human plasma solutions that mimic in vivo environment. 
Human serum albumin (HSA), one of the most abundant proteins in the blood, was used for pre-
coating as a control. These pre-coating significantly altered protein corona compositions when 
the pre-coated nanoparticles were exposed to the diluted human plasma. In particular, γ-
globulins pre-coating recruited significantly more opsonins to the protein corona as compared to 
the HSA pre-coated nanoparticles or the bare nanoparticles. Pre-coating the nanoparticles with 
γ-globulins increased their uptake by RAW 264.7 mouse macrophage cells compared to the 
bare nanoparticles. However, the cellular uptake of these nanoparticles was significantly 
decreased when a protein corona was formed on the γ-globulin pre-coated silica nanoparticles. 
The cellular uptake of nanoparticles that were functionalized with a protein corona were similar 
regardless of whether or not they were pre-coated with γ-globulins even though the opsonin 
content was higher in the protein coronas of the γ-globulin pre-coated nanoparticles. Our finding 
indicates that the protein corona shielded the opsonins from interacting with the surface 
receptors on the cells, thereby compromising the targeting. This suggests that for efficient 
targeting, the spatial distribution of the target moieties on the nanoparticles should be 
considered more important than their overall abundance in the protein corona.   
 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Unless otherwise indicated, all chemicals were purchased from Sigma-Aldrich. 
Carboxyethyl-silanetriol sodium salt, 25% in water, was purchased from Gelest Inc. 
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Concentrated ammonia was purchased from Fisher Scientific. The bicinchoninic acid (BCA) 
colorimetric protein assay kit was obtained from Pierce Biotechnology. 4-20% polyacrylamide 
precast gels and QC Colloidal Coomassie Stain were purchased from Bio-Rad. The MSG-
Trypsin for protein digestion was purchased from G-Biosciences (St. Louis, USA). Clarity 
Western ECL substrate was obtained from Bio-Rad. The glass-bottomed dishes for confocal 
fluorescence microscopy were purchased from CellVis. Paraformaldehyde was purchased from 
Electron Microscopy Sciences. Rabbit anti-CD64 antibody (sc-15364) was purchased from 
Santa Cruz Biotechnology. Alexa488 goat anti-rabbit IgG, Hoechst 33342 nuclear stain, Image-
iT FX Signal Enhancer, and OptiMEM serum free media were purchased from Life 
Technologies. RAW 264.7 cells were kindly provided by Prof. Ed Roy (University of Illinois at 
Urbana-Champaign, USA). 
5.2.2 Synthesis of carboxylic acid-functionalized silica nanoparticles and carboxylic acid-
functionalized fluorescent silica nanoparticles  
The silica nanoparticles were synthesized and functionalized as previously described.22 
5.2.3 Preparation of HSA, γ-globulin pre-treated nanoparticles and hard corona 
nanoparticles 
The silica nanoparticles were pre-coated with HSA and γ-globulin following the published 
protocol.22 The hard corona was formed as described in the same publication.22 
5.2.4 Measurement of the sizes and zeta potentials of the nanoparticles 
The zeta-potential and size measurements for the uncoated (control) nanoparticles (UC-
NPs), HSA pre-coated nanoparticles (HSA-NPs) the γ-globulin pre-coated nanoparticles (GG-
NPs), and the nanoparticles coated with a protein corona (corona-UC-NPs, corona-HSA-NPs, 
and corona-GG-NPs) were performed in OptiMEM using a Brookhaven ZetaPALS instrument. 
Scanning electron microscopy (SEM) was also used to measure the size of the nanoparticles. 
UC-NPs, protein pre-coated nanoparticles, and nanoparticles with hard-coronas were placed on 
5 mm x 5 mm silicon substrates and coated with Au/Pd using an Emitech K575 sputter coater. 
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The nanoparticles were imaged with a Hitachi S-4800 high-resolution scanning electron 
microscope. For each sample, the sizes of 50 nanoparticles were measured using ImageJ.  
5.2.5 Measurement of the amount of protein on the nanoparticles 
The amounts of proteins on the nanoparticles were quantified using a BCA assay as 
previously described.22 
5.2.6 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of 
hard corona  
The proteins on the nanoparticles were denatured by heating the nanoparticles in 
Laemmli sample buffer for 5-10 min at 85 °C and separated by electrophoresis on 4-20% 
polyacrylamide precast gels. The resulting gels were fixed in fixing solution (40% methanol, 
10% acetic acid and 50% water), stained with QC Colloidal Coomassie Stain overnight and 
destained in water for 2-3 h. Stained gels were imaged using an Image Quant LAS4010 image 
analyzer (GE Healthcare).  
5.2.7 Identification of the protein corona composition by LC-MS/MS  
The composition of the protein corona on each type of nanoparticle was identified by LC-
MS/MS analysis, as described in the previous publication.22 
5.2.8 Cell culture  
RAW 264.7 cells (mouse macrophages) were cultured in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin in a 5% CO2 incubator at 37°C.  
5.2.9 Flow cytometry analysis to evaluate cellular uptake of the nanoparticles 
RAW 264.7 cells were used when they reached 50-70% confluence. The nanoparticles 
were suspended in the medium to make final concentration of 20 μg/mL immediately prior to 
incubation with cells. OptiMEM was used for serum-free culture conditions and DMEM with 10% 
FBS was used for experiments performed in the presence of serum. The cells were washed with 
PBS, incubated with nanoparticles in the appropriate medium for 2 or 6 h, and subjected to flow 
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cytometry after thorough washing. The flow cytometry was performed with BD LSR II Flow 
Cytometry Analyser using a blue laser and a 575/26 bandpass filter.  
5.2.10 Immunodot-blot assay for assessing ligand availability on the nanoparticles 
The nanoparticles (GG-NPs, corona-GG-NPs, and corona-UC-NPs) in PBS (250 μg/mL) 
were spotted onto a pre-wetted polyvinylidene fluoride (PVDF) membrane and dried. Next, the 
membranes were blocked with 5% skim milk in PBS for 1 h on a shaker at room temperature, 
and incubated with goat anti-human IgG, IgM, IgA antibody (Jackson ImmunoResearch, 109-
005-064) in 1% skim milk in PBS overnight at 4 °C. Membranes were washed three times with 
PBS for 5 min each, incubated with HRP-conjugated rabbit anti-goat antibody, and washed 
three times with PBS at room temperature. The resulting membrane was visualized by 
chemiluminescence and imaged using ImageQuant LAS 4000 Imager (GE Healthcare). 
5.2.11 Confocal fluorescence microscopy 
The cells were grown in glass-bottomed dishes and used for microscopy when they 
reached 50-70% confluence. The cells were washed with PBS and incubated with the 
nanoparticles in the same concentration as used for the corresponding flow cytometry 
experiment for 2 h in OptiMEM for serum-free culture conditions. Next, the cells were washed 
thoroughly with medium and PBS, and fixed with 4% paraformaldehyde for 15 min at room 
temperature. The nanoparticles were visualized with LSM700 confocal fluorescence microscope 
(Carl Zeiss) using a 555 nm laser for excitation of the nanoparticles. To assess whether the 
nanoparticle uptake was receptor mediated, RAW 264.7 cells grown on glass-bottomed petri 
dishes were incubated with nanoparticles in OptiMEM (concentration = 20 μg/mL) for 2 h, and 
then were washed with OptiMEM. The cells were fixed with 4% paraformaldehyde for 15 min at 
room temperature, and permeabilized with 0.1% Triton-X 100 in PBS for 10 min on ice. To 
prevent nonspecific binding, the samples were blocked with Image-iT FX Signal Enhancer (Life 
Technologies) for 30 min followed by 1% BSA in PBS for 20 min at room temperature. Then the 
cells were incubated with rabbit anti-CD64 in 1% BSA in PBS overnight at 4°C. After washing 
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with 1% BSA in PBS 3 times, the samples were incubated with Alexa488 goat anti-rabbit IgG in 
1% BSA in PBS, and washed three times with 1% BSA in PBS. Cell nuclei were stained with 
Hoechst 33342 following manufacturer’s protocol for 15 min at room temperature. The cells 
were imaged with a LSM700 (Carl Zeiss) confocal microscope using a 555 nm, 488 nm, and 
405 nm laser for excitation of the nanoparticles, CD64, and nuclei, respectively.  
 
5.3 RESULTS 
5.3.1 Characterization of γ-globulin and HSA pre-coated silica nanoparticles with and 
without protein corona 
Carboxyl acid-functionalized silica nanoparticles were chemically conjugated to either γ-
globulin or HSA. A BCA assay confirmed the presence of the proteins on the nanoparticles. 
EDC/NHS-activated silica nanoparticles had significantly more proteins than unactivated 
nanoparticles, which suggests that the proteins were chemically conjugated as well as 
physically adsorbed to the nanoparticles. To confirm covalent conjugation of the γ-globulin to the 
nanoparticles, the nanoparticles were treated with SDS to desorb physically bound proteins and 
subjected to a BCA assay. At least 60% of the γ-globulin remained on the nanoparticles even 
after SDS treatment. This indicates that the majority of the γ-globulin protein was covalently 
attached to the silica nanoparticles.  
Next, the protein coronas were prepared on the naked (uncoated) nanoparticles, and the 
HSA and γ-globulin conjugated nanoparticles. To mimic the protein concentration in vivo and in 
cell culture, human plasma was diluted in PBS at final concentration of 55% and 10%, 
respectively, and these diluted plasma solutions were used for protein corona formation. The 
nanoparticles were incubated with the diluted human plasma solutions for 1 h at 37°C, and then 
were washed to remove the loosely bound proteins.  
The sizes and zeta potentials of naked or uncoated nanoparticles (UC-NPs), HSA pre-
coated nanoparticles (HSA-NPs), γ-globulin pre-coated nanoparticles (GG-NPs), and the human 
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plasma-exposed nanoparticles without a pre-coating (corona-UC-NPs), pre-coated with HSA 
(corona-HSA-NPs) and γ-globulin (corona-GG-NPs) were characterized. The hydrodynamic 
diameters, diameters measured with SEM, and the zeta potentials of the nanoparticles are 
shown in Table 5.1. Pre-coating of the nanoparticles with HSA and γ-globulins significantly 
increased their hydrodynamic diameters, size distributions, and zeta potentials measured by 
DLS. The increased hydrodynamic diameters and size distributions could be indicative of 
particle aggregation, and not a thick layer of protein. Therefore, the sizes and the size 
distributions of the nanoparticles were also measured using SEM. The SEM measurements 
showed that indeed, some types of nanoparticles, especially the protein pre-coated 
nanoparticles, namely the HSA-NPs and GG-NPs, had aggregated. The increases in size 
resulting from the protein pre-coating on the individual nanoparticles were less than 10 nm (5 
nm and 9 nm for HSA-NPs and GG-NPs respectively).  
The nanoparticles that had been functionalized with a protein corona were also 
characterized. The hydrodynamic diameters of the corona-HSA-NPs and corona-GG-NPs were 
larger than those of the corona-UC-NPs, but smaller than those of the HSA-NPs and GG-NPs, 
the parent nanoparticles that lacked a protein corona. The SEM images indicated that protein 
corona formation seem to reduce the clustering of the protein pre-coated nanoparticles. When 
measured by SEM, the increased diameters resulting from protein corona formation on the 
individual nanoparticles were approximately 9 nm and 3 nm for HSA-NPs and GG-NPs, 
respectively. These are very small differences in comparison to the difference in the sizes of the 
between UC-NPs and corona-UC-NPs. This indicates that the loosely bound proteins from the 
pre-coating step were exchanged for plasma proteins during protein corona formation.  
5.3.2 Characterization of protein corona composition using SDS-PAGE and LC-MS/MS 
Next, to assess the influence of the pre-coating on the protein corona composition, the 
proteins of corona-HSA-NPs, corona-GG-NPs and UC-corona-NP were characterized. The 
proteins that were deposited onto the nanoparticles during the pre-coating step were identified 
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(marked in black in Figure 5.2) by comparing the protein bands with the protein pre-coated 
nanoparticles that were not exposed to human plasma. The protein profiles for those three 
corona-coated particles were fairly similar, but the intensities of the protein bands were 
significantly different, as marked in red in Figure 5.2.  
The protein corona composition of each type of nanoparticle was analyzed further with 
LC-MS/MS. The weight percent of each protein detected by LC-MS/MS was calculated using an 
exponentially modified protein abundance index (emPAI), as described in the literature.23 The 
ten most abundant in the protein coronas of the nanoparticles are listed in Table 5.2.  
The proteins detected in the protein corona of each nanoparticle were classified by their 
functions. As expected, the γ-globulin pre-coating enriched the protein corona with 
immunoglobulins and complement factors compared to the corona-HSA-NPs and the corona-
UC-NPs. About 40% of the proteins detected in corona-GG-NPs were identified as 
immunoglobulins. In contrast, the portion of lipoproteins in the protein corona increased 
significantly when the nanoparticles had been pre-coated with HSA. Considering the amount of 
proteins measured on the GG-NPs and corona-GG-NPs, the pre-coated γ-globulins were 
estimated to make up about 55% of the immunoglobulins (and about 22% of total proteins) that 
were detected in the protein corona of the corona-GG-NPs. This result supports the hypothesis 
that the γ-globulin pre-coating recruits opsonins, such as immunoglobulins and complement 
factors, in the plasma to the protein corona.  
5.3.3 Assessment of the cellular uptake of nanoparticles with and without the protein 
corona 
We examined whether the high portion of opsonins in the protein corona increased the 
cellular uptake of the nanoparticles by macrophage cells. The opsonins, such as the 
complement factors and immunoglobulins, on the nanoparticles could interact with the receptors 
on the immune cells and initiate particle internalization. For example, immunoglobulins can bind 
to the Fc receptors on macrophages, which initiates nanoparticle internalization. However, the 
		93 
unactivated complement factors that were detected in the protein corona of the nanoparticles in 
this study are not reported to interact with immune cells. Therefore, we used RAW 264.7 mouse 
macrophage cells to investigate whether the enrichment of the protein corona with 
immunoglobulins increased nanoparticle internalization.  
To measure the relative amount of internalized nanoparticles, fluorescent silica 
nanoparticles with and without the γ-globulin pre-coating were prepared as described above. 
Then the protein corona was formed by incubation in 55% human plasma solution for 1 h at 
37°C, and washing in PBS. The RAW 264.7 cells were incubated with the resulting corona-UC-
NPs and corona-GG-NPs in serum-free medium for 2 h at 37°C. After thorough washing, the 
cells were then examined with confocal fluorescence microscopy to visualize the internalized 
nanoparticles, or flow cytometry to quantify the amount of the nanoparticles inside the cells.  
Although the corona-GG-NPs had a significantly higher portion of immunoglobulins in 
their protein corona than the corona-UC-NPs, the confocal fluorescence microscopy and flow 
cytometry experiments indicated little difference in the amounts of corona-GG-NPs and corona-
UC-NPs internalized by RAW 264.7 cells. In contrast, confocal fluorescence microscopy showed 
that the GG-NPs, the γ-globulin pre-coated particles that were not exposed to the human 
plasma solution, were internalized substantially more than the nanoparticles functionalized 
protein coronas. This observation was also confirmed by flow cytometry. This finding indicates 
that the hard corona formed by exposing the GG-NPs to 55% human plasma solution shielded 
the immunoglobulins on the nanoparticle surface from interacting with their cellular receptors 
despite their high levels in the protein corona. The presence of serum in the cell culture medium 
(10% v/v) during nanoparticle incubation with the RAW 264.7 cells did not affect the uptake of 
GG-NPs, suggesting that the nanoparticles were rapidly internalized before the serum proteins 
could deposit on their surfaces and shield the γ-globulins. In addition, this indicates that the 
lowered cellular uptake of corona-GG-NPs compared to GG-NPs was due to the proteins on the 
surface of the particles, and not because of the presence of soluble proteins in the culture 
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solution inhibited nanoparticle uptake. These results indicate that protein corona formation 
hinders the interactions between the immunoglobulins on corona-GG-NPs and the Fc receptors 
on the RAW 264.7 cells, thereby lowering the internalization of the corona-GG-NPs.  
5.3.4 Evaluation of the interactions between opsonins on the nanoparticles and cellular 
Fc receptors  
We further investigated whether the lowered cellular uptake of the corona-GG-NPs was 
because protein corona formation compromised specific interactions between the opsonins on 
the particles and the cellular Fc receptors. First, we compared the availability of the 
immunoglobulins on the GG-NPs, corona-GG-NPs, and corona-UC-NPs to binding partners by 
using immunodot blotting. A significantly higher level of immunoglobulins was detected on the 
surfaces of the GG-NPs than either type of nanoparticle that was coated with a protein corona. 
Even though LC-MS/MS detected more immunoglobulins were in the corona-GG-NPs than the 
corona-UC-NPs, the immunoglobulin levels detected on both corona-coated nanoparticles by 
immunodot-blot differed only slightly, indicating the availability of the immunoglobulins was 
compromised by protein corona formation. When GG-NPs were incubated in cell culture 
medium supplemented with 10% serum for 1 h, the availability of the immunoglobulins 
decreased to that of the corona-GG-NPs. Considering the similar levels of cellular uptake for the 
GG-NPs in serum-free medium and 10% serum-supplemented medium (Figure 5.5), this 
suggests that internalization of the nanoparticles occurs faster than the change in protein 
composition on the surface of the nanoparticles that could alter the extent of the nanoparticle 
uptake. 
Next, we evaluated whether cellular uptake of the nanoparticles by RAW 264.7 
macrophage cells involved interactions between the immunoglobulins on the nanoparticles and 
the cellular Fc receptors. The cells were allowed to internalize the GG-NPs, corona-GG-NPs, 
and corona-UC-NPs for 2 h, and then were washed and chemically fixed. Then CD64 (also 
known as FcγRI), a Fc receptor that has a high affinity for IgG, on the RAW 264.7 cells were 
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labeled by immunofluorescence and visualized in parallel with the nanoparticles using confocal 
fluorescence microscopy (Figure 5.7). The GG-NPs were internalized significantly more than the 
other two types of nanoparticles, which is consistent with the data shown in Figure 5.4. More 
importantly, colocalization of GG-NPs with CD64 was higher than CD64 colocalization with the 
corona-GG-NPs and corona-UC-NPs. This indicates that these nanoparticles were internalized 
by a Fc receptor-mediated mechanism, and the presence of the other corona proteins hindered 
interactions between the immunoglobulins and the CD64 on the cell surface.  
Overall, our data indicates that in spite of the higher amount of immunoglobulins on the 
surface of the nanoparticles, the other proteins that adsorb onto the nanoparticles during corona 
formation could prevent the immunoglobulins from interacting with the cellular Fc receptors, 
which lowers internalization of the nanoparticles.   
 
5.4 DISCUSSION 
We investigated whether pre-coating nanoparticles with selected proteins can be used to 
recruit a certain subset of plasma proteins to the protein corona for nanoparticle targeting. 
Although the prevention of opsonin-mediated nanoparticle endocytosis is typically desirable for 
anticancer therapy in clinical settings in order to obtain longer circulation times, we utilized this 
mechanism to test the feasibility of manipulating protein corona composition for nanoparticle 
targeting. Opsonin-mediated endocytosis is an ideal model system for evaluating the cellular 
uptake of the nanoparticles because the endocytosis mechanism that is elicited by the binding 
of opsonins to their cellular receptors is well established.18,24  
We showed that composition of the protein corona can be manipulated by chemically 
conjugating certain proteins to the nanoparticle surface. The compositions of the protein 
coronas that formed on the uncoated, HSA pre-coated, and γ-globulin pre-coated nanoparticles 
were noticeably different. The pre-coating itself contributed to some of the differences in protein 
corona composition. However, the pre-coating also altered the identities of the plasma proteins 
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that were recruited to the protein corona. For example, the HSA pre-coating reduced the amount 
of fibrinogen in the protein corona. Fibrinogen binding onto the nanoparticle surface can initiate 
an immune response by inducing inflammatory cytokine release,19,25,26 therefore the reduction of 
fibrinogen content in the protein corona that formed on the HSA pre-coated nanoparticles could 
contribute to the increased circulation time of albumin-coated drugs in the body.27,28 The γ-
globulin pre-coating enriched the protein corona with opsonins, whereas almost no 
immunoglobulins were detected in the protein corona that formed on the HSA pre-coated and 
uncoated nanoparticles.  
Receptor mediated endocytosis, more specifically phagocytosis, is likely the dominant 
mechanism of nanoparticle internalization observed in this study. Confocal fluorescence 
microscopy images clearly show that CD64, which is a Fc receptor with high affinity to IgG, was 
colocalized with the γ-globulin–pre-coated nanoparticles. Fc receptors are reported to be rapidly 
and selectively degraded after internalization.29 Interestingly, CD64 fluorescence was markedly 
more intense when higher levels of nanoparticles were detected in the cells (Figure 5.7). This 
implies that the nanoparticles internalized with the Fc receptors may prevent Fc receptor 
degradation and slow down their turnover.  
The finding that higher opsonin content in the protein corona does not translate to higher 
cellular uptake suggests that protein corona formation obstructs the direct interactions of the 
immunoglobulins with the cellular Fc receptors. Despite the noticeable difference in the protein 
corona composition, the availability of the immunoglobulins (Figure 5.6) and the cellular uptake 
of the corona-GG-NPs and corona-UC-NPs (Figure 5.5, and Figure 5.7) were only slightly 
different, and almost comparable. This suggests that the outermost proteins in the protein 
coronas that coated these particles lacked an affinity for the surface proteins, such as Fc 
receptors, on the RAW 264.7 cells.  
The presence of 10% serum in the culture media did not alter the uptake of GG-NPs by 
RAW 264.7 cells (Figure 5.5), while nanoparticle incubation with this medium for 1 h reduced 
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the immunoglobulins’ ability to interact with antibodies (Figure 5.6), and thus, Fc receptors on 
the cell surface. This indicates that the receptor-mediated internalization of the nanoparticles in 
in vitro cell cultures (without agitation) likely occurs before the serum proteins are able to adsorb 
onto the nanoparticles. However, nanoparticles in vivo move quickly within the blood stream and 
encounter more proteins and metabolites than nanoparticles in a cell culture. Therefore, 
exposing the nanoparticles to biological fluid (i.e. plasma) in vitro using the proper conditions, 
such as using enough agitation at the physiological temperature prior to cell culture, would more 
closely mimic the uptake of nanoparticles in vivo and provide a more accurate projection for the 
outcome in vivo.   
Overall, we showed that pre-coating nanoparticles with selected proteins may enrich the 
protein corona with certain plasma proteins that may be useful for targeting. However, the 
availability of the recruited target proteins may be compromised by the protein corona if other 
inactive corona proteins cover the targeting proteins. Therefore, the spatial orientation of the 
desired proteins in the corona must be carefully regulated for efficient nanoparticle targeting.  
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5.6 FIGURES AND TABLES 
 
 
 
Figure 5.1. The sizes and the size distributions of the nanoparticles used in this study. A: SEM 
images and B: the corresponding size distribution of the pre-coated nanoparticles. C: SEM 
images and D: the corresponding size distributions of the corona-coated nanoparticles. Scale 
bars in A and C indicate 500 nm. 
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Figure 5.2. Detection of the proteins on the pre-coated nanoparticles (A) and in the protein 
coronas that formed on the nanoparticles by exposure to human plasma solutions (B) by SDS-
PAGE. The black stars indicate the bands produced by the pre-coated proteins. The red stars 
represent the proteins that were detected in all samples but vary in intensity between the 
samples.  
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Figure 5.3. Comparison and functional characterization of the corona proteins. The proteins 
identified by LC-MS/MS analyses of the protein coronas on each type of nanoparticle, and were 
classified according to their biological functions in the blood.  
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Figure 5.4. Confocal microscopy images of RAW 264.7 cells incubated with A: corona-UC-NPs, 
B: corona-GG-NPs, and C: GG-NPs (which were not exposed to plasma). The fluorescence 
images were overlaid on the DIC images of the same locations. Note that the cellular uptake of 
the GG-NPs was significantly higher than that of the other two types of corona-coated 
nanoparticles. Scale bars indicate 20 μm. 
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Figure 5.5. Comparison and quantification of nanoparticle uptake using flow cytometry. Flow 
cytometry curves for the uptake of different types of nanoparticles in A: serum-free medium, and 
B: 10% serum-supplemented medium. C: quantification of the flow cytometry results.  
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Figure 5.6. Immunodot blot comparison of the accessibility of the immunoglobulins on the 
surfaces of the nanoparticles. A: Antibody binding to the accessible immunoglobulins on (1) 
corona-UC-NPs, (2) corona-GG-NPs, (3) GG-NPs, and (4) GG-NPs that had been exposed to 
DMEM supplemented with 10% serum. Darker color signifies higher antibody binding, and thus, 
higher immunoglobulin accessibility in the protein corona. The immunoglobulins on the GG-NPs 
(3) were the most accessible. B: The immunoglobulins accessible to antibody binding in the 
standard dilution solution for immunoblotting (1% skim milk) or typical cell culture medium, 
which contains 10% FBS. Immunoglobulin detection by antibody only slightly decreased in the 
presence of serum. 
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Figure 5.7. Confocal fluorescence microscopy images of each type of nanoparticle in parallel 
with immunolabeled CD64, a Fc receptor. RAW 264.7 cells were incubated with the 
nanoparticles for 2 h and then fixed and immunolabeled against CD64. The cell nuclei were 
stained with Hoechst 33342. Red: nanoparticles; green: immolabeled CD-64; blue: nuclei 
stained with Hoechst 33342. Scale bars are 20 μm.  
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Table 5.1. Characterization of nanoparticle ζ-potential, diameter (d, hydrodynamic diameter 
measured with DLS), size distribution (polydispersity index, PDI), and diameter measured with 
SEM.  
 
Type of NPs ζ-potential (mV) d, hydrodynamic (nm) PDI d, SEM (nm) 
UC-NPs -29.83 ± 3.00 94.5 ± 1.1 0.086 93.1 ± 14.1 
HSA-NPs -17.03 ± 1.54 343.9 ± 10.0 0.338 98.0 ± 10.5 
GG-NPs -12.79 ± 2.08 749.2 ± 19.6 0.336 101.9 ± 12.8 
corona-UC-NPs -10.18 ± 1.02 157.9 ± 3.0  0.282 102.3 ± 13.3 
corona-HSA-
NPs -8.00 ± 3.22 212.8 ± 1.9 0.223 101.3 ± 12.7 
corona-GG-NPs -7.19 ± 3.17 292.6 ± 11.6 0.353 101.8 ± 11.5 
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Table 5.2. Ten most abundant proteins detected by LC-MS/MS in each protein corona 
 
corona-UC-NPs corona-HSA-NPs corona-GG-NPs 
Apolipoprotein E Apolipoprotein E Apolipoprotein B100 
Apolipoprotein E chain A Apolipoprotein E4 chain A Apolipoprotein E 
Alpha fibrinogen Kininogen-1 Ig gamma-1 heavy chain 
Apolipoprotein C3 chain A Serum albumin Ig heavy chain 
Fibrinogen chain A Apolipoprotein B100 Ig M chain C 
Apolipoprotein B100 Gelsolin Histidine-rich glycoprotein 
Gelsolin Histidine-rich glycoprotein Complement C3 
Tetranectin Apolipoprotein C3 chain A Complement C4-A 
Kininogen-1 Apolipoprotein J Proapolipoprotein 
Serum albumin Plasminogen Fibrinogen alpha chain 
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CHAPTER 6 
CONCLUSIONS AND FUTURE OBJECTIVES 
 
We established metabolic labeling methods that may be used to study the behavior of 
cellular sphingolipids using two different tags, fluorophores and stable isotopes. With the 
fluorophore-tagged sphingosines, we were able to visualize and track sphingolipids and their 
metabolites within cells. Stable isotope labeling offered a novel opportunity to investigate 
sphingolipid metabolism more comprehensively than with the traditional use of radioactive 
labels. We also investigated whether sphingolipids affect influenza virus infection. Lastly, we 
demonstrated that the adsorption of undesired proteins to the nanoparticle during protein corona 
formation impairs the active targeting of nanoparticles by covering the plasma proteins that were 
recruited to the corona due to their targeting capabilities. Consequently, the spatial orientation of 
the plasma proteins with targeting capabilities within the corona must be controlled for efficient 
active targeting.  
Chapter 2 describes the use of fluorescent sphingosines for labeling and visualizing 
sphingolipids and their metabolites in cells. BODIPY 540 sphingosine was designed and 
developed to enable labeling and visualizing both sphingolipids and their metabolites. We 
confirmed that BODIPY 540 sphingosine was metabolized following native sphingolipid 
metabolic pathways. Interestingly, compared to BODIPY sphingosine, BODIPY 540 sphingosine 
produced more BODIPY 540 glycerophospholipids than BODIPY 540 sphingolipids in NIH3T3 
mouse fibroblast cells. The cause of this difference in the metabolism of these two fluorescent 
sphingosines is of interest. The subcellular location of the BODIPY 540 sphingosine metabolites 
was observed in conjunction with distinct organelle markers. The BODIPY 540 sphingosine 
metabolites were located at the ER, the Golgi apparatus and the mitochondria at 30 min post-
labeling and were transported out of these organelles over time, primarily to the plasma 
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membrane. Their abundance at the lysosomes was low at 30 min post-labeling compared to 
other organelles, but this abundance increased over time, likely due to (sphingo)lipid 
catabolism. In summary, we demonstrated that BODIPY 540 sphingosine is a useful tool to 
investigate sphingolipid metabolism and subcellular localization, and possibly for use in vitro 
assays.  
The other labeling method to study sphingolipid behavior was demonstrated in Chapter 
3. When combined with imaging mass spectrometry, such as secondary ion mass spectrometry 
performed with a NanoSIMS instrument, stable isotope labeling is a valuable tool for visualizing 
cellular lipids. Here we showed that stable isotope labeled sphingoid bases and mass 
spectrometry detection can not only provide the same information as radioactive labeling, a 
traditional tool to study sphingolipid metabolism and behavior, but it also yields additional 
information about the unlabeled species. Recently developed high mass resolution mass 
spectrometry techniques facilitate the use of stable isotope-labeled sphingolipid precursors by 
provided a highly specific detection mechanism. Our lipidomics analysis of unlabeled lipid from 
NIH3T3 mouse fibroblast cells revealed that C16-SM is the major sphingolipid, accounting for 
about 60% of all sphingolipid species. The incorporation of 15N-sphingoid bases and 13C-fatty 
acids over various labeling times were assessed using LC-MS analysis. The pattern of 15N-
sphingoid base incorporation into ceramide and sphingomyelin was similar to that of 3H-
sphingosine, clearly showing that stable isotope labeling can be used as a substitute for 
radioactive labeling.  
Overall, in Chapter 2 and Chapter 3, we developed tools to metabolically label 
sphingolipids with fluorescence tags and stable isotopes. One drawback of these metabolic 
labeling approaches is that the exogenously added labels can change the flux of metabolic 
products in the cells. Because the labels and their immediate metabolites, ceramides, are 
proapoptotic, their addition may also adversely affect cell growth. Therefore, the labeling 
conditions should be carefully chosen based on the purpose of the labeling and the cell’s ability 
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to tolerate the labels. Investigations that are carefully designed to perturb distinct pathways in 
sphingolipid metabolism (such as using inhibitors of certain steps in sphingolipid metabolism or 
labeling with only 15N-sphingosine instead of both 15N-sphingosine and 15N-sphinganine) will 
enable closer scrutiny of sphingolipid metabolism and ultimately, deciphering the intertwined 
sphingolipid biosynthesis and catabolic pathways. In order to obtain a more complete 
understanding of sphingolipid metabolism, trafficking, and function, the secreted sphingolipids 
would also need to be analyzed, which would be facilitated by pulse-chase labeling. 
The involvement of sphingolipids, in particular those generated by aSMase, in influenza 
virus infection was investigated in Chapter 4. Prior to virus infection, aSMase in the cells and in 
conditioned culture media was detected by Western blot. Our data clearly show that a significant 
amount of aSMase was secreted, while this enzyme was barely detected in the cell lysates. 
Even though sphingolipids have been shown to regulate the entry of many pathogens into cells, 
under our experimental conditions, influenza virus entry decreased by only 20% when the 
aSMase level was lowered through use of siRNAs and a functional inhibitor, desipramine. 
Desipramine treatment significantly decreased virus particle release 8 hpi, but knockdown of 
SMPD1 was not as effective as desipramine treatment. This suggests that the inhibitory effect of 
desipramine treatment on the infection may be attributed to its biological actions other than 
inhibiting aSMase. We revealed that influenza virus entry led to an upregulation of SMPD1 
levels in the cells, which implies that aSMase may be involved in an early phase of influenza 
virus infection. More studies are needed to verify the potential role of acid sphingomyelin in 
influenza virus infection. Such work will need to use other methods, such as overexpression or 
complete knockdown by genome editing, to manipulate the aSMase levels in the host cells. 
These studies have the potential to markedly improve our understanding of sphingolipid 
functions and their roles in infection.  
Finally, in Chapter 5, we showed that the protein corona, the protein layer that forms on 
nanoparticles when they are exposed to biological fluids, such as whole blood or plasma, can 
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be manipulated, prior to protein corona formation, by coating the nanoparticles with proteins that 
have an affinity for the subset of the plasma proteins with the desired targeting capabilities. 
Opsonin mediated endocytosis in immune cells was utilized as a model system to evaluate the 
feasibility of manipulating the protein corona composition and its effects on cellular uptake. We 
demonstrate that, although the protein pre-coating increases the abundance of the desired 
plasma proteins in the protein corona, the adsorption of other plasma proteins to the 
nanoparticle during protein corona formation significantly reduces nanoparticle uptake by 
preventing the targeting proteins on the nanoparticles from binding to their targets on the cell 
surface. Our data suggest that in addition to the abundance of the targeting proteins in the 
protein corona, their orientations must also be regulated to attain more efficient targeted 
nanoparticle delivery.  
	
